Introduction {#s1}
============

Prdm14 is a sequence-specific transcriptional regulator that plays key roles in promoting primordial germ cell (PGC) specification and safeguarding pluripotency of embryonic stem cells (ESCs) ([@bib45]). During mouse embryogenesis, Prdm14 is expressed in preimplantation embryos, where its asymmetric expression promotes allocation of cells toward the pluripotent inner cell mass (ICM) fate ([@bib5]; [@bib45]). Prdm14 expression ceases in postimplantation epiblast cells and their differentiated progeny. However, during PGC specification from the epiblast, cells reacquire many transcriptional and epigenetic characteristics of the preimplantation state, and Prdm14 is re-expressed along with several other pluripotency-associated factors (reviewed in \[[@bib40]; [@bib60]\]). The loss of Prdm14 in mice results in sterility associated with early germ cell deficiency, as cells fated to become PGCs fail to reacquire expression of key pluripotency factors and undergo epigenetic reprogramming ([@bib70]). Furthermore, overexpression of Prdm14 in epiblast-like cells (EpiLCs) is sufficient to induce PGCs in vitro (albeit with low frequency), suggesting a central role of Prdm14 in the mouse PGC regulatory network ([@bib41]; [@bib44]). Furthermore, Prdm14 is repressed in normal somatic tissues but is aberrantly reactivated in human malignancies of various tissue origin, including leukemias and lymphomas, breast, testicular, and lung cancers ([@bib6]; [@bib15]; [@bib47]; [@bib59]; [@bib73]).

Given the poor accessibility and transient nature of preimplantation embryo cells and PGCs in vivo, mechanistic studies of Prdm14 function in early development have been chiefly conducted in the context of mouse ESCs (mESCs). These cells represent a so-called \'naïve\' pluripotent state, thought to resemble preimplantation embryo ICM and serve as a useful system for understanding early cell fate decisions ([@bib46]). Loss of Prdm14 destabilizes mESCs and sensitizes them to differentiation stimuli, leading to acquisition of alternative embryonic states, such as the postimplantation epiblast state or extraembryonic endoderm state, and eventual depletion of the naïve cell subpopulation ([@bib38]; [@bib71]). The differentiation in Prdm14^−/−^ cells is thought to result from upregulation of signaling pathways such as the fibroblast growth factor receptor (FGFR) pathway and by widespread DNA hypermethylation ([@bib23]; [@bib25]; [@bib36]). Indeed, genome-wide Prdm14 occupancy studies by chromatin immunoprecipitation with sequencing (ChIP-seq) suggest that these are direct effects of the loss of Prdm14, as Prdm14 occupies and represses the regulatory elements of genes involved in FGFR signaling and de novo DNA methylation ([@bib36]; [@bib38]; [@bib41]; [@bib71]). Nonetheless, Prdm14^−/−^ mESCs can be maintained indefinitely under 2i conditions ([@bib23]; [@bib52]; [@bib71]), in which differentiation stimuli, including FGFR signaling, are chemically inhibited, providing an opportunity to study the early effects of Prdm14 deficiency upon release from such inhibition.

Although the cellular and molecular phenotypes associated with loss of Prdm14 in mESCs have been well characterized, much less is known about molecular mechanisms and partners through which Prdm14 acts. As a member of the PRDM family, Prdm14 contains both a zinc-finger array, responsible for sequence-dependent DNA binding ([@bib38]), and a PR domain that is related to the SET domain (Su(var)3--9, Enhancer-of-zeste and Trithorax) ([@bib19]; [@bib30]). Many SET domains harbor methyltransferase activity for either histone or non-histone substrates ([@bib13]). However, to date, no enzymatic activity has been reported for Prdm14, and interestingly multiple members of the PRDM family appear to be catalytically inactive. Instead, candidate-based co-immunoprecipitation studies implicated Polycomb complex PRC2 as a mediator of Prdm14-dependent repression ([@bib7]; [@bib71]). Nonetheless, it remains unclear whether PRC2 is a major or auxiliary partner of Prdm14, and what other molecular players are important for Prdm14\'s function.

To address these questions, we used an unbiased biochemical approach to uncover major Prdm14-associated proteins in mESCs. We identified an ETO-family corepressor, myeloid translocation gene related 1 (Mtgr1, a.k.a. Mtg8r, Cbfa2t2, and Zmynd3), as a direct, stoichiometric partner of Prdm14. We demonstrate that Mtgr1 co-occupies Prdm14 target loci, and its deletion in mESCs results in phenotypes and gene expression defects similar to those observed upon loss of Prdm14. Moreover, Mtgr1 knockout cells show impaired induction of PGC-like cells in vitro. To further facilitate studies of the Prdm14-Mtgr1 complex, we mapped interaction domains and developed multiple synthetic binding proteins, termed monobodies, that specifically recognize the SET domain of Prdm14 in a manner independent of, or alternatively, competitive with Mtgr1. Taking advantage of the stabilizing effect of one such monobody, we obtained a crystal structure of the Prdm14-Mtgr1 complex, revealing an extensive interface and electrostatic interactions mediating the association of the two proteins. Furthermore, structure-guided mutagenesis of the interface and the use of an inhibitory monobody demonstrated the function of the complex in safeguarding pluripotency and PGC-like cell induction. Altogether, we report a multi-disciplinary study that advances our understanding of Prdm14 function, identifying Mtgr1 as the major partner of Prdm14 in its roles in pluripotency and PGC induction, and providing the community with renewable, genetically encoded reagents that can be used both in vitro and in vivo to study and control Prdm14 function in development and malignancy.

Results {#s2}
=======

Identification of Mtgr1 as a novel Prdm14 partner {#s2-1}
-------------------------------------------------

To identify Prdm14 partners in an unbiased manner, we employed a two-step immunopurification strategy (FLAG followed by HA \[FH\]) from a previously described clonal mESC transgenic line stably expressing tagged FH-Prdm14 ([@bib38]). Examination of recovered proteins by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and silver staining revealed two major polypeptides that were present in similar quantities in the FH-Prdm14 purifications, but not in the control immunoprecipitates ([Figure 1A](#fig1){ref-type="fig"}). These polypeptides were subsequently identified by mass spectrometry as Prdm14 and Mtgr1 ([Figure 1A](#fig1){ref-type="fig"}, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}), the latter of which is one of the three members of the ETO family of co-repressors ([@bib12]). Mass spectrometry analysis also identified additional polypeptides enriched uniquely in the FH-Prdm14 purifications, including the other two ETO proteins Mtg8 and Mtg16, their known repressive complex partners Tbl1/Tblr1 and histone deacetylases (HDACs), as well as Brg1 complex components and Oct4, among others ([Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). Of note, we did not detect components of the Polycomb complex PRC2 ([@bib7]; [@bib71]).10.7554/eLife.10150.003Figure 1.Prdm14 directly binds to the ETO family protein, Mtgr1.(**A**) Two-step immunoaffinity purification of Prdm14-associated proteins. FLAG--HA immunoprecipitations were performed from wild-type (wt) or FH-Prdm14 mESC extracts, followed by visualization of polypeptides by SDS-PAGE-silver stain and mass spectrometry identification. Polypeptides corresponding to Mtgr1 and Prdm14 are highlighted. (**B**) Reciprocal Mtgr1 and Prdm14 co-immunoprecipitations from FH-Prdm14 mESCs. (**C**, **D**) Identification of the Prdm14-Mtgr1 interaction regions. Co-immunoprecipitations were performed in HEK293 cells transfected with full-length V5-tagged Mtgr1 and distinct FH-Prdm14 constructs (****C****) or full-length FH-Prdm14 and distinct V5-Mtgr1 constructs (****D****), as indicated in the top diagrams; co-immunoprecipitated proteins were visualized by immunoblotting with α-HA (Prdm14) and α-V5 (Mtgr1) antibodies (top left and right panels, respectively). Tagged Prdm14 and Mtgr1 levels in the input extracts are shown in the bottom panels. (**E**) Recombinant biotinylated Prdm14 (pre-SET+SET) was immobilized on streptavidin-coated beads and incubated with recombinant Mtgr1 (NHR1), and changes in fluorescence (SAV-Dylight650) were measured. (**F, G**) Recombinant biotinylated Mtgr1 (NHR1) was immobilized on streptavidin-coated beads and incubated with (****F****) Prdm14 (pre-SET+SET) or (****G****) Prdm14 (SET) and changes in fluorescence (SAV-Dylight650) were measured. The error bars and the errors for the *K*~D~ values are the standard deviation (n = 3). The curves show the best fit of the 1:1 binding model using the GraphPad software. \* indicates non-specific bands. HEK, human embryonic kidney; Mtgr1, myeloid translocation gene related 1; MW, molecular weight marker; NHR1, nervy homology region 1. N.D., not determined.**DOI:** [http://dx.doi.org/10.7554/eLife.10150.003](10.7554/eLife.10150.003)10.7554/eLife.10150.004Figure 1---source data 1.List of proteins recovered from the Prdm14 IP-MS experiment.**DOI:** [http://dx.doi.org/10.7554/eLife.10150.004](10.7554/eLife.10150.004)10.7554/eLife.10150.005Figure 1---figure supplement 1.Expression levels of mRNAs encoding ETO proteins.Plotted are RPKM values for Mtgr1, Mtg1 and Mtg16 obtained in RNA-seq experiments from mESC grown under serum+LIF or 2i+LIF conditions or from EpiLCs. EpiLCs, epiblast-like cells; LIF, leukemia inhibitory factor; mESC, mouse embryonic stem cell; Mtgr1, myeloid translocation gene related 1; RNA-seq, RNA sequencing; RPKM, reads per kilobase of exon per million reads mapped.**DOI:** [http://dx.doi.org/10.7554/eLife.10150.005](10.7554/eLife.10150.005)

Mtgr1 was the major polypeptide identified in our analysis and its stoichiometric recovery in our purifications indicated it might represent a strong and direct partner of Prdm14. To confirm this, we first verified Prdm14 and Mtgr1 association using reciprocal co-immunoprecipitations from mESC nuclear extracts ([Figure 1B](#fig1){ref-type="fig"}). Next, we mapped the minimal regions within Prdm14 and Mtgr1 that were required for the interaction by overexpressing differentially-tagged proteins (V5-Mtgr1 and FH-Prdm14) in HEK293 cells, followed by IP-Western analysis ([Figure 1C, D](#fig1){ref-type="fig"}). This strategy revealed that the nervy homology region 1 (NHR1) domain of Mtgr1 was necessary and sufficient for the interaction with Prdm14, whereas both Prdm14 SET domain and the region directly preceding it (pre-SET) were important for efficient binding to Mtgr1 ([Figure 1C, D](#fig1){ref-type="fig"}). To quantify the strength of the Prdm14--Mtgr1 interaction, we next expressed and purified recombinant proteins corresponding to the NHR1 domain of Mtgr1 (residues 98--206) and pre-SET+SET domains of Prdm14 (residues 184--373), and performed a bead-based binding assay in reciprocal orientations ([@bib48]). The obtained binding measurements yielded a dissociation constant (*K*~D~) in the low nanomolar range ([Figure 1E and F](#fig1){ref-type="fig"}), which is consistent with a robust, direct interaction between the two proteins. On the other hand, the binding of the Prdm14 SET domain alone (residues 232--373) to the Mtgr1 NHR1 domain was barely detectable ([Figure 1G](#fig1){ref-type="fig"}), further supporting that both pre-SET and SET domains are required for the high affinity interaction with Mtgr1.

Altogether, our approach identified an ETO protein Mtgr1 as a novel, direct partner of Prdm14 in mESCs. While the ETO proteins, especially Mtg8 (a.k.a. ETO), have been studied in the context of acute myeloid leukemias (AML) (reviewed in [@bib26]), their function in ESCs and during early embryogenesis has not been explored. Notably, all three ETO family members have the capacity to interact with Prdm14 (not shown), but the high expression of Mtgr1 in mESCs compared with Mtg8 and Mtg16 ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) likely accounts for the preferential recovery of Mtgr1 in our experiments and suggests that this family member may be most relevant in the context of mESCs. We therefore proceeded to explore the functional significance of the Prdm14--Mtgr1 interaction in mESC biology.

Prdm14 and Mtgr1 co-occupy genomic targets {#s2-2}
------------------------------------------

Prdm14 is a sequence-dependent DNA-binding protein that binds many genomic loci in mESCs, corresponding primarily to distal regulatory elements, whereas ETO proteins do not contain domains implicated in direct DNA sequence recognition ([@bib57], [@bib58]). To examine whether Mtgr1 is brought to genomic targets occupied by Prdm14, we performed Mtgr1 ChIP coupled with high-throughput DNA sequencing (ChIP-seq) from wt mESCs, *FH-Prdm14* overexpressing mESCs, and as a control for antibody specificity, *Mtgr1^−/−^* mESCs (generation of which is described in more detail later), cultured for 5 days under serum+leukemia inhibitory factor (LIF) conditions. In parallel, we profiled Prdm14 occupancy by performing ChIP-seq analysis from *FH-Prdm14* cells, using an anti-HA antibody due to the unavailability of ChIP-grade Prdm14 antibodies. Overall, we identified \~ 8000 Mtgr1 peaks present in both *FH-Prdm14* and wt mESCs, but absent in *Mtgr1^−/−^* mESCs. These bound sites include loci known to be occupied and repressed by Prdm14 (e.g. near *Prdm14, Dnmt3b, Wnt8a, Peg10,* and targets of the FGFR pathway *Fgfr2 and Shc1*; [Figure 2A](#fig2){ref-type="fig"}).10.7554/eLife.10150.006Figure 2.Prdm14 and Mtgr1 co-occupy genomic targets.(**A**) Prdm14 and Mtgr1 ChIP-seq enrichments at selected gene loci. Tracks represent sequence tag enrichments as determined by Quest software. (**B**) Scatter plot of Prdm14 and Mtgr1 genomic occupancies in FH-Prdm14 mESC line. (**C**) The top sequence motif recovered in Mtgr1 ChIP-seq corresponds to the Prdm14 motif, as defined previously ([@bib38]). Logos for the consensus motifs were generated using SeqPos. (**D**) Scatter plot of Mtgr1 genomic occupancy in wt and FH-Prdm14 mESC lines. The plot is colored based on the presence of Prdm14 motif (red, motif is present, p-value \<10^-3^; black, motif is absent). ChIP-seq, chromatin immunoprecipitation with sequencing; mESC, mouse embryonic stem cell; Mtgr1, myeloid translocation gene related 1.**DOI:** [http://dx.doi.org/10.7554/eLife.10150.006](10.7554/eLife.10150.006)10.7554/eLife.10150.007Figure 2---figure supplement 1.Genomic occupancy of Mtgr1.(**A**) Correlation coefficient, R, between Mtgr1 and Prdm14 (anti-HA) ChIP-seq genomic occupancy levels in two different clonal FH-Prdm14 mESC lines. (**B**) Functional annotation categories of the Mtgr1 binding sites in FH-Prdm14 mESCs as determined by GREAT. ChIP-seq, chromatin immunoprecipitation with sequencing; GREAT, genomic regions enrichment of annotations tool; mESCs, mouse embryonic stem cell; Mtgr1, myeloid translocation gene related 1.**DOI:** [http://dx.doi.org/10.7554/eLife.10150.007](10.7554/eLife.10150.007)10.7554/eLife.10150.008Figure 2---figure supplement 2.Genomic occupancy of Mtgr1 at Prdm14 motif-lacking sites.(**A**) Genomic tracks at select Prdm14 motif-lacking Mtgr1 binding sites. Note that these sites lack Prdm14 binding and Mtgr1 peaks are present in wt cells, but not in the FH-Prdm14-overexpressing line. (**B**) Aggregate plots of Mtgr1 ChIP-seq enrichments at Prdm14 motif-containing (left) or Prdm14 motif-lacking (right) Mtgr1 sites from indicated ESC cell lines. (**C**) Top five motifs recovered from the Mtgr1-binding sites where Prdm14 motif was absent. ChIP-seq, chromatin immunoprecipitation with sequencing; ESC, embryonic stem cell; Mtgr1, myeloid translocation gene related 1; wt, wild type.**DOI:** [http://dx.doi.org/10.7554/eLife.10150.008](10.7554/eLife.10150.008)

Generally, the genomic occupancies of Mtgr1 and Prdm14 were well correlated (correlation coefficient \~0.9, [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}), and we have not been able to detect a substantial class of Prdm14-bound sites devoid of Mtgr1 occupancy ([Figure 2B](#fig2){ref-type="fig"}). Not surprisingly, the Prdm14 and Mtgr1 sites shared common functional ontologies, with enrichment for processes involved in embryonic development and cell differentiation ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). Furthermore, the most highly enriched DNA sequence motif at Mtgr1-bound sites corresponded to the previously identified Prdm14 motif ([Figure 2C](#fig2){ref-type="fig"}). Interestingly, we noted that, at many targets, Mtgr1 binding was enhanced by Prdm14 overexpression (see tracks in [Figure 2A](#fig2){ref-type="fig"}, compare wt and *FH-Prdm14* ESC). This observation prompted us to quantitatively compare Mtgr1 ChIP-seq enrichments in wt ESCs and *FH-Prdm14* cells that are characterized by \~5-fold overexpression of Prdm14. We observed that Mtgr1 enrichments were higher in *FH-Prdm14* than in wt ESCs at most target sites, consistent with Prdm14-mediated recruitment of Mtgr1 to chromatin ([Figure 2D](#fig2){ref-type="fig"}). However, we also noticed that a subset of Mtgr1 sites was bound more weakly in *FH-Prdm14* cells than in wt ESCs ([Figure 2D](#fig2){ref-type="fig"}, examples shown in [Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). The major distinction between these two populations was the presence of the Prdm14 sequence motif and Prdm14 occupancy at the sites where Mtgr1 binding was enhanced by Prdm14 overexpression, and lack of the Prdm14 sequence motif with low/no Prdm14 occupancy at the sites where Mtgr1 binding was diminished by Prdm14 overexpression ([Figure 2D](#fig2){ref-type="fig"}). Of note, at the Prdm14 motif-lacking sites, the most enriched sequence motifs corresponded to helix-loop-helix transcription factor recognition sites, suggesting that a TF from this family may be involved in mediating Mtgr1 binding at these sites ([Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"}). Regardless, our results indicate that Prdm14 is sufficient to augment interaction of Mtgr1 with chromatin at its cognate binding sites and, at high levels, redirect it away from the motif-lacking sites. Thus, Prdm14 might be a limiting factor for Mtgr1 recruitment to chromatin. To test this notion further, we performed Mtgr1 ChIP-seq analysis from Prdm14^−/−^ ESCs and generated average signal profiles at Prdm14 motif-containing and Prdm14 motif-lacking sites across all our Mtgr1 ChIP-seq datasets. We observed that at Prdm14 motif-containing sites, Mtgr1 binding is increased in FH-Prdm14 overexpressing cells and diminished (but not completely abrogated) in Prdm14^−/−^ cells ([Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}, left panel). On the other hand, at Prdm14 motif-lacking sites, Mtgr1 binding is depleted by FH-Prdm14 overexpression, but it is also moderately affected in Prdm14^−/−^ cells despite low/no Prdm14 binding at these sites, suggesting an indirect effect ([Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}, right panel). Altogether, these results are consistent with the Mtgr1 genomic occupancy being sensitive to the Prdm14 dosage (either loss or gain) at the Prdm14-motif containing sites. However, these results also demonstrate that even in the absence of Prdm14, some Mtgr1 binding remains at the motif-containing sites, suggesting partial redundancies in the recruitment mechanisms.

Loss of Mtgr1 phenocopies requirement for Prdm14 in safeguarding pluripotency {#s2-3}
-----------------------------------------------------------------------------

Prdm14 has well-characterized roles in pluripotency and PGC formation, and if Mtgr1 is a key mediator of Prdm14\'s functions then the loss of Mtgr1 should impact these processes in a similar manner. To test this hypothesis, we used CRISPR-Cas9 with a guide RNA targeting the third exon of the *Mtgr1* gene to generate *Mtgr1^−/−^* mESCs, and verified the presence of the homozygous deletions and loss of the Mtgr1 protein in the three clonal lines selected for further analysis ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). As a reference for comparison, we also isolated and characterized two *Prdm14^−/−^* mESC lines by targeting the second exon of the *Prdm14* gene ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Moreover, we reconstituted each of the *Mtgr1^−/−^* and *Prdm14^−/−^* cell lines with *FH-Mtgr1* or *FH-Prdm14* complementary DNA (cDNA), respectively, to generate \'rescue\' cell lines and ensure specificity of the observed phenotypes. All aforementioned cell lines were isolated and maintained under the serum-free 2i+LIF conditions in which the major differentiation cues are inhibited and that support self-renewal even in the absence of Prdm14 ([@bib23]; [@bib71]). After being transferred into standard serum+LIF growth conditions, the *Mtgr1^−/−^* lines exhibited changes in morphological appearance with less compact colonies, diminished cell--cell interactions and cell flattening, as previously reported for loss of Prdm14 in mESCs and reproduced here with our *Prdm14^−/−^* lines ([@bib38]; [@bib71]) ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). These features were not observed in wt mESCs or after rescue with the respective protein constructs ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}).

Loss of Prdm14 has been shown to sensitize mESC to differentiation stimuli, resulting in upregulation of genes associated with epiblast and extraembryonic endoderm fates ([@bib38]; [@bib71]). To examine whether these molecular phenotypes are also observed upon loss of Mtgr1, we conducted RNA sequencing (RNA-seq) transcriptome analyses from wt mESCs, *Prdm14^−/−^* and *Mtgr1^−/−^* cell lines, and their respective rescue lines after transfer from 2i+LIF to serum+LIF conditions. As seen in *Prdm14^−/−^* mESCs, *Mtgr1^−/−^* mESCs showed upregulation of epiblast (e.g. *Fgf5, Dnmt3b, Oct6, Wnt8a*) and extraembryonic endoderm (e.g. *Krt19, Sparc, H19, Fgfr2*) markers, and downregulation of naïve pluripotency genes (e.g. *Esrrb, Zfp42, Tbx3, Tet2*), compared with either wt or *FH-Mtgr1* rescue mESCs ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 4A](#fig3s4){ref-type="fig"}).10.7554/eLife.10150.009Figure 3.Loss of Mtgr1 phenocopies requirement for Prdm14 in safeguarding pluripotency and PGC induction.(**A**) RNA-seq from *Prdm14^−/−^* cells or *Mtgr1^−/−^* cells (y-axis) were compared to wt cells (x-axis) and expression values (RPKM) of all significantly changed transcripts were plotted. Select transcripts corresponding to those enriched in the post-implantation epiblast, extraembryonic endoderm or naïve pluripotent mESC are highlighted in red, green or blue, respectively; shaded colors indicate no significant difference. (**B**) Heatmap displaying top 100 variable genes between wt mESCs grown under naïve 2i+LIF or serum+LIF conditions, *Prdm14*^−/−^ (2 clones) or *Mtgr1*^−/−^ (3 clones) cells, and their respective rescue lines. Clustering represents sample divergence. (**C**) Principal component analysis on the same populations as in B. (**D**) mESC to mEpiLC transition followed by PGC-LC induction using defined media in cells containing *Stella*:GFP reporter. Schematic of the *Stella*:GFP transgene reporter that contains a 10kb 5' upstream sequence and includes exon 1 and part of exon 2 fused in-frame with eGFP, followed by the SV40 polyadenylation sequence ([@bib51]). The reporter is active in mPGC-LCs when *Stella* expression is activated. (**E**) Quantification of the GFP signal in wt cells during the mESC to mEpiLC and further to mPGC-LC transition. (**F**) FACS plots and gated quantification of GFP signal as a measure of mPGC-LC induction from wt cells, *Prdm14*^−/−^ cells or Prdm14 rescue clones. (**G**) FACS plots and quantification of GFP signal as a measure of PGC-LC induction from wt cells, *Mtgr1*^−/−^ cells or Mtgr1 rescue clones. FACS, fluorescence-activated cell sorting; GFP, green fluorescent protein; LIF, leukemia inhibitory factorm; EpiLCs, mouse epiblast-like cells; mESCs, mouse embryonic stem cell; mPGC-LCs, mouse primordial germ cell-like cells; Mtgr1, myeloid translocation gene related 1; RPKM, reads per kilobase of exon per million reads mapped; wt, wild-type.**DOI:** [http://dx.doi.org/10.7554/eLife.10150.009](10.7554/eLife.10150.009)10.7554/eLife.10150.010Figure 3---figure supplement 1.Generation of Mtgr1-null line in *Stella:*GFP mESCs using CRISPR-Cas9 system.(**A**) Schematic of the *Mtgr1* gene and sequence of the guide RNA (<http://crispr.mit.edu/>). (**B**) Genomic and cDNA were extracted and chromatograms of the wt (top), mutant A3 line (clone 1), mutant C1 line (clone 2), and mutant C3 line (clone 3) are shown. (**C**) Indel spectrum centered around the PAM sequence was performed using software TIDE (<http://tide.nki.nl/>). Clones A3, C1, and C3 are shown, they all produce aberrant transcript. (**D**) Western blotting of the whole cell lysate from the wt, A3, C1 and C3 mESC *Stella:*GFP line. CRISPR, clustered regularly interspaced short palindromic repeat; GFP, green fluorescent protein; PAM, protospacer adjacent motif; mESCs, mouse embryonic stem cells; Mtgr1, myeloid translocation gene related 1; wt, wild type.**DOI:** [http://dx.doi.org/10.7554/eLife.10150.010](10.7554/eLife.10150.010)10.7554/eLife.10150.011Figure 3---figure supplement 2.Generation of Prdm14-null line in *Stella:*GFP mESCs using CRISPR-Cas9 system.(**A**) Schematic of the *Prdm14* gene and sequence of the guide RNA (<http://crispr.mit.edu/>). (**B**) Genomic and cDNA were extracted and chromatograms of the wt (top), mutant G6 line (clone 1), and mutant F10 line (clone 2) are shown. (**C**) Indel spectrum centered around the PAM sequence was performed using software TIDE (<http://tide.nki.nl/>). Clone G6 is shown on top and clone F10 below. Clones G6 and F10 produce aberrant transcript. cDNA, complementary DNA; CRISPR, clustered regularly interspaced short palindromic repeat; GFP, green fluorescent protein; mESCs, mouse embryonic stem cells; wt, wild type.**DOI:** [http://dx.doi.org/10.7554/eLife.10150.011](10.7554/eLife.10150.011)10.7554/eLife.10150.012Figure 3---figure supplement 3.Morphological changes associated with loss of Prdm14 or Mtgr1.Brighfield images of cell morphology from wt ESCs, *Prdm14^−/−^* or *Mtgr1^−/−^*ESCs or those reconstituted with wt FH-Prdm14 or FH-Mtgr1, respectively, all grown under serum+LIF conditions; wt ESC maintained in 2i+LIF are included for relative comparisons (upper left image). ESC, embryonic stem cell; LIF, leukemia inhibitory factor; Mtgr1, myeloid translocation gene related 1; wt, wild type.**DOI:** [http://dx.doi.org/10.7554/eLife.10150.012](10.7554/eLife.10150.012)10.7554/eLife.10150.013Figure 3---figure supplement 4.Additional analyses of RNA-seq datasets.(**A**) RNA-seq from *Prdm14*^−/−^ cells or *Mtgr1*^−/−^ cells (y axis) were compared with respective rescue lines (x axis) and expression values (RPKM) of all significantly changed transcripts were plotted. The transcripts of specific genes are highlighted in red, green or blue as indicated; shaded colors indicate no significant difference. (**B**) Scatter plot of genes upregulated at least twofold upon loss of either Prdm14 or Mtgr1. Highlighted in blue are genes significant for Mtgr1-null cells only, red -- Prdm14-null only, magenta -- genes significantly upregulated in both cell lines. Mtgr1, myeloid translocation gene related 1; RNA-seq, RNA sequencing; RPKM, reads per kilobase of exon per million reads mapped. **DOI:** [http://dx.doi.org/10.7554/eLife.10150.013](10.7554/eLife.10150.013)10.7554/eLife.10150.014Figure 3---figure supplement 5.Expression of differentiation markers in embryoid bodies derived from wt or Mtgr1^−/−^ ESCs.(**A**) RT-qPCRs analyses of indicated markers in EBs induced from wt or Mtgr1^−/−^ ESCs and cultured for four days in suspension after LIF withdrawal; shown relative to wt mESCs cultured under serum+LIF conditions. (**B**) RT-qPCRs analyses of select markers in EBs induced from wt or Mtgr1^−/−^ ESCs and cultured for eight days in suspension after LIF withdrawal; shown relative to wt mESCs cultured under serum+LIF conditions. ESCs, embryonic stem cells; LIF, leukemia inhibitory factor; Mtgr1, myeloid translocation gene related 1; RT-qPCRs, quantitative reverse transcription-polymerase chain reaction; wt, wild type.**DOI:** [http://dx.doi.org/10.7554/eLife.10150.014](10.7554/eLife.10150.014)10.7554/eLife.10150.015Figure 3---figure supplement 6.Loss of Mtgr1 results in defect in PGC-LC induction.(**A**) Imaging of fixed mPGC-LCs on day 6 of differentiation using bright field, DAPI (stained with Hoechst) and GFP channels. Imaging was done using z-stacks and maximum projection was taken afterwards. (**B**) FACS on the *Stella*:GFP line in ES state or PGC-LC state as indicated. Wt cells or Prdm14-null, Mtgr1-null or respective rescue lines were used. DAPI, 4\',6-diamidino-2-phenylindole; GFP, green fluorescent protein; FACS, fluorescence-activated cell sorting; mPGC-LCs, mouse primordial germ cell-like cells; wt, wild type; Mtgr1, myeloid translocation gene related 1.**DOI:** [http://dx.doi.org/10.7554/eLife.10150.015](10.7554/eLife.10150.015)

Next, we identified genes showing the most variable expression across our datasets and visualized their expression changes in each of our RNA-seq datasets as a heatmap ([Figure 3B](#fig3){ref-type="fig"}). Most of the differentially expressed genes were concordantly upregulated in *Prdm14*^−/−^ and *Mtgr1*^−/−^ cells, compared with wt mESCs, in agreement with the proposed function of the Prdm14--Mtgr1 complex in gene repression. A more systematic comparison of all genes upregulated at least twofold upon loss of either Prdm14 or Mtgr1 revealed that while indeed, the majority of genes that are upregulated in either knockout are upregulated in both ([Figure 3---figure supplement 4B](#fig3s4){ref-type="fig"}, purple dots), a subset of transcripts is preferentially affected only in one of the knockouts (red or blue dots).

Importantly, in the *FH-Prdm14* or *FH-Mtgr1* reconstituted knockout cells the derepression defects were rescued ([Figure 3B](#fig3){ref-type="fig"}). Interestingly, while *FH-Mtgr1* cells showed expression patterns highly similar to that of wt mESCs cultured in serum, *FH-Prdm14* cells were more similar to the mESCs grown under 2i +LIF, despite being cultured in serum at the time of analysis ([Figure 3B](#fig3){ref-type="fig"}). Indeed, many of the expression differences observed between wt mESC grown in 2i versus serum were recapitulated in *FH-Prdm14* mESCs ([Figure 3B](#fig3){ref-type="fig"}). Of note, a subset of transcripts was upregulated only in *FH-Prdm14* cells; many of those genes represent markers of the so-called 2-cell (2C) state ([@bib3]; [@bib9]; [@bib39]).

In our analysis of variably expressed genes, the *Prdm14*^−/−^ and *Mtgr1*^−/−^cell lines clustered together, but separately from the respective rescue lines and wt mESCs ([Figure 3B](#fig3){ref-type="fig"}). These observations were further confirmed by the global comparisons of transcriptomes with principal component analysis (PCA), in which the *Prdm14*^−/−^ and *Mtgr1*^−/−^cells were closest to each other and clustered away from the remaining cell lines ([Figure 3C](#fig3){ref-type="fig"}). Additionally, the PCA analysis corroborated higher similarity of *FH-Mtgr1* cells to wt mESCs grown in serum+LIF, and *FH-Prdm14* cells to wt mESCs grown under 2i+LIF conditions ([Figure 3C](#fig3){ref-type="fig"}). Given that: (i) the *FH-Prdm14* cell lines in our study express Prdm14 at levels \~5--6-fold higher than wt ESCs, (ii) Prdm14 has an autonomous DNA-binding activity, and (iii) Prdm14 overexpression can augment Mtgr1 recruitment to the target genes (as shown in [Figure 2](#fig2){ref-type="fig"}), we propose that expression changes observed in *FH-Prdm14* cell lines are associated with more robust repression of differentiation programs by Prdm14-Mtgr1 complex compared with wt cells and consequently, with the stabilization of the naïve pluripotency program. Similar gain-of-function effects are not observed in *FH-Mtgr1* cells, likely because Mtgr1 lacks the autonomous ability to access its genomic targets and, at least in mESCs, Prdm14 is limiting for its chromatin association. Altogether, our data uncover the function of Mtgr1 in safeguarding mESC pluripotency and demonstrate that loss of Mtgr1 phenocopies gene expression defects associated with Prdm14 deletion.

Mtgr1 is required for PGC specification in vitro {#s2-4}
------------------------------------------------

Prdm14 is critical for the specification of PGCs from the post-implantation epiblast cells ([@bib40]; [@bib70]). To address whether Mtgr1 also plays a role in PGC formation, we used a previously established in vitro model in which naïve mESCs are first differentiated to a primed, post-implantation epiblast-like state (mEpiLCs) from which mouse primordial germ cell-like cells (mPGC-LCs) are then induced via addition of various cytokines ([@bib28]; [@bib27]). The mPGC-LCs formation is monitored with the fluorescent reporter, *Stella*:GFP and quantified by fluorescence-activated cell sorting (FACS) analysis ([Figure 3D](#fig3){ref-type="fig"}). In vitro derived mPGC-LCs have been shown to be competent to differentiate to sperm/oocytes upon transplantation and produce viable, fertile offspring and this simple in vitro differentiation system is therefore considered a useful tool to study mechanisms underlying PGC specification ([@bib27]; [@bib44]). To examine the role of Prdm14 and Mtgr1 in the context of this model, we derived *Prdm14*^−/−^ and *Mtgr1*^−/−^ mESCs in the *Stella*:GFP reporter background; this reporter recapitulates endogenous *Stella* induction that occurs during the PGC formation ([@bib51]).

In agreement with previous reports, differentiation of *Stella*:GFP mESCs consistently produced mPGC-LCs with an efficiency of \~7--8% on day 6 of differentiation, while low levels (\~1%) of GFP-positive cells were detected in mESCs and further diminished upon mEpiLC formation ([Figure 3E](#fig3){ref-type="fig"}). In contrast, both *Prdm14*^−/−^ and *Mtgr1*^−/−^ mESCs showed significantly decreased efficiency of mPGC-LCs formation ([Figure 3F and G](#fig3){ref-type="fig"}, [Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}). These defects were rescued by the re-introduction of *FH-Prdm14* or *FH-Mtgr1*, respectively ([Figure 3F and G](#fig3){ref-type="fig"}, [Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}). These data suggest that Mtgr1, like Prdm14, is important for mouse PGC establishment. Significantly, loss of Mtgr1 does not result in general block in differentiation, as germ layer markers are expressed at comparable levels in embryoid bodies induced from *Mtgr1*^−/−^ versus wt ESCs ([Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}).

Generation of renewable monobody reagents to study and inhibit Prdm14-Mtgr1 interaction {#s2-5}
---------------------------------------------------------------------------------------

To develop new tools for understanding the function of Prdm14 and to aid structure determination, we generated designer binding proteins termed 'monobodies' recognizing the SET domain of human and mouse Prdm14, as a part of a larger project aimed at developing new reagents for controlling epigenetic regulatory proteins. Monobodies are small binding proteins (\~10 kDa) generated from combinatorial phage-display libraries built on the antibody-like scaffold of the tenth human fibronectin type III domain (FN3; [Figure 4A](#fig4){ref-type="fig"}) ([@bib32], [@bib33]). Monobodies can recognize their targets with high affinity and specificity and have a strong tendency to recognize functional binding sites in their target molecules including clefts and planar surfaces, and thus they often are potent inhibitors ([@bib34]; [@bib61]; [@bib68]). Furthermore, unlike antibodies whose folding depends on disulfide bond formation, monobodies are cysteine-free and thus functional when expressed under reducing environments such as the nucleus and cytoplasm. These attributes make monobodies particularly attractive as genetically encoded intracellular inhibitors.10.7554/eLife.10150.016Figure 4.Generation of PRDM14-binding monobodies.(**A**) Schematic of the monobody scaffold. The β strands and loops are labeled and the diversified residues are marked as red spheres. The amino acid sequences of the monobody library and monobody clones. In the library designs, 'X' denotes a mixture of 30% Tyr, 15% Ser, 10% Gly, 5% Phe, 5% Trp, and 2.5% each of all the other amino acids except for Cys; 'O', a mixture of Asn, Asp, His, Ile, Leu, Phe, Tyr, and Val; 'U', a mixture of His, Leu, Phe, and Tyr; 'Z', a mixture of Ala, Glu, Lys, and Thr ([@bib34]). A hyphen indicates a deletion. (**B**) Titration curves of Mb(hPRDM14_S4) and Mb(hPRDM14_S14) to human PRDM14 and mouse Prdm14. The error bars are the standard deviation (n = 3). The curves show the best fit of the 1:1 binding model. (**C**) Binding of Mb(S4) and Mb(S14) expressed on yeast surface to 50 nM of hPRDM14 and its homologues, mouse Prdm14, human PRDM12 and human PRDM6. (**D**) Competitive binding assay for Mtgr1 and monobodies. Binding of 10 nM Mtgr1 to biotinylated Prdm14 immobilized on streptavidin coated M280 beads in the absence and presence of 500 nM purified monobodies, Mb(S4) and Mb(S14). (**E**) Co-immunoprecipitation of FLAG--HA tagged Prdm14 expressed in mESC using Mb(S4), Mb(S14), α-FLAG M2 antibody or a negative control antibody ('IgG'). Antibodies used for Western blotting are indicated with the blots. E, elution; FT, flow through; Mtgr1, myeloid translocation gene related 1.**DOI:** [http://dx.doi.org/10.7554/eLife.10150.016](10.7554/eLife.10150.016)10.7554/eLife.10150.017Figure 4---figure supplement 1.Sequences of monobodies selected against human PRDM14 and their K~D~ values to hPRDM14 measured in yeast display format.Two types of libraries were used, loop and side library. In the library designs, \'X\' denotes a mixture of 30% Tyr, 15% Ser, 10% Gly, 5% Phe, 5% Trp, and 2.5% each of all the other amino acids except for Cys, \'B\', a mixture of Gly, Ser and Tyr, \'J\', a mixture of Ser and Tyr, \'O\', a mixture of Asn, Asp, His, Ile, Leu, Phe, Tyr, and Val, \'U\', a mixture of His, Leu, Phe and Tyr, \'Z\', a mixture of Ala, Glu, Lys and Thr (Koide et al. 2012). A hypen indicates a deletion.**DOI:** [http://dx.doi.org/10.7554/eLife.10150.017](10.7554/eLife.10150.017)10.7554/eLife.10150.018Figure 4---figure supplement 2.Human PRDM14 can substitute for the mouse Prdm14 in mESCs.(**A**) Morphological changes in Prdm14^−/−^ mESCs and those reconstituted with mouse or human FH-PRDM14 cDNA, respectively. Note that all lines were grown under serum+LIF conditions. (**B**) Western blot shows that both human and mouse Prdm14 proteins were expressed at similar levels in the reconstituted lines. (**C**) RT-qPCRs measuring changes in gene expression in lines reconstituted with human or mouse Prdm14 relative to the Prdm14^−/−^ line. Genes marked with an asterisk denote direct mouse Prdm14 targets from ChIP-seq. ChIP-seq, chromatin immunoprecipitation with sequencing; LIF, leukemia inhibitory factor; RT-qPCRs, quantitative reverse transcription-polymerase chain reaction.**DOI:** [http://dx.doi.org/10.7554/eLife.10150.018](10.7554/eLife.10150.018)10.7554/eLife.10150.019Figure 4---figure supplement 3.Monobody affinity pulldown of the endogenous Prdm14 protein.(**A**) Co-precipitation of Mtgr1 with endogenous Prdm14 from wt mESC extracts via affinity pulldown with Mb(S4), Mb(S14) or, as a negative control, beads only followed by detection of Mtgr1 by Western blotting. (**B**) Silver staining of polypeptides recovered in the affinity pulldown with Mb(S4) from wt mESC extracts. (**C**) Mass spectrometry analysis of proteins recovered in the affinity pulldown with Mb(S4) from wt mESC extracts. Results of the top recovered and correctly matched proteins (prob \>5.00; prob -- log probability of the correct fit to the data) are shown. Also shown are total intensity, number of spectra and number of unique peptides recovered, percent coverage and number of amino acids in the recovered protein. E, elution; FT, flow through; mESC, mouse embryonic stem cell; Mtgr1, myeloid translocation gene related 1; W, wash; wt, wild type.**DOI:** [http://dx.doi.org/10.7554/eLife.10150.019](10.7554/eLife.10150.019)

We isolated Prdm14-binding monobodies from two combinatorial phage display libraries termed the 'loop' library and the 'side' library ([@bib34]). Following phage display selection, we performed gene shuffling for affinity maturation and further selection in the yeast display format to isolate clones with high affinity. We identified a total of 12 clones that bound to human PRDM14 (hPRDM14) with *K*~D~ \<100 nM as measured by yeast surface display ([Figure 4A](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Among them, we identified two clones, Mb(hPRDM14_S4) and Mb(hPRDM14_S14), that bound hPRDM14 (residues 238--487) at least five-fold stronger than the closest homologues, hPRDM6 (residues 194--405) and hPRDM12 (residues 60--229) ([Figure 4C](#fig4){ref-type="fig"}). We will use shorthand names, Mb(S4) and Mb(S14), for referring to them hereafter for brevity. Additionally, these two monobodies showed comparable binding to the mouse homologue of hPRDM14, Prdm14. Of note, hPRDM14 was able to substitute for the mouse Prdm14 in rescue of the Prdm14^-/-^ ESC defects, suggesting both biochemical and biological conservation of function between mouse and humans ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}).

We produced these two monobodies as purified proteins for further characterization. Consistent with analysis using yeast surface display, these purified monobodies showed high affinity with *K*~D~ \<50 nM to both hPRDM14 and Prdm14 in bead-based assays ([Figure 4B](#fig4){ref-type="fig"}). We then examined whether these monobodies inhibited the interaction of Prdm14 with Mtgr1. Mb(S14) potently competed against the binding of Mtgr1 to Prdm14 but Mb(S4) did not ([Figure 4D](#fig4){ref-type="fig"}). This result suggests that the two monobodies bind to distinct surfaces of Prdm14 and the epitope for Mb(S14) overlaps with and therefore occludes the Mtgr1-binding surface ([Figure 4D](#fig4){ref-type="fig"}).

We next tested whetherif these monobodies can immunoprecipitate Prdm14 from mESC lysates. Mb(S4) captured Prdm14 and co-immunoprecipitated vast majority of Mtgr1 from the *FH-Prdm14* cell extracts ([Figure 4E](#fig4){ref-type="fig"}). On the other hand, Mb(S14) captured lower levels of Prdm14 , in agreement with its competition for the same binding surface as Mtgr1 ([Figure 4E](#fig4){ref-type="fig"}). Since PRC2 complex has been previously reported to associate with Prdm14 ([@bib7]; [@bib52]; [@bib71]), we also looked for the presence of Suz12, a PRC2 component. We did not detect immunoprecipitated Suz12 in the elution fraction for either of the two monobodies. Next, we used monobodies to precipitate endogenous Prdm14 from wt ESCs. Immunoblot analysis with α-Mtgr1 antibody showed that Mb(S4) monobody, which does not disrupt Prdm14-Mtgr1 interaction, recovered endogenous Mtgr1 (and was able to deplete most of it from the extract, [Figure 4---figure supplement 3A and B](#fig4s3){ref-type="fig"}). In addition, we performed Prdm14 Mb(S4)-precipitation/mass spec analysis from wt ESCs, which readily detected Prdm14- and Mtgr1-originating peptides, but did not recover any other PRDM proteins confirming a high specificity of this monobody ([Figure 4---figure supplement 3B and C](#fig4s3){ref-type="fig"}). Common to monobodies generated to recognize native, folded proteins, neither Mb(S4) nor Mb(S14) detected denatured Prdm14 in immunoblotting (not shown). Overall, we report here the generation of the first recombinant affinity reagents targeting two distinct sites of Prdm14 SET domain.

Monobody- and fusion-assisted crystal structure determination of the Prdm14-Mtgr1 complex {#s2-6}
-----------------------------------------------------------------------------------------

To understand how Prdm14 and Mtgr1 interact at the atomic level, we attempted crystallization of the Prdm14-Mtgr1 complex. However, aggregation of both proteins resulted in low yields of the complex suitable for crystallization. To overcome this problem, we designed a fusion construct of Prdm14 and Mtgr1 in which the two proteins were linked with a ten-residue linker (GSSGSSGS), a common strategy for stabilizing heterodimers ([@bib18]; [@bib31]; [@bib56]; [@bib74]). To confirm that the linker did not distort the Prdm14--Mtgr1 complex, we performed a series of experiments. The fusion protein had the same retention time on size-exclusion chromatography as the unlinked complex ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}), indicating that the linker did not alter the stoichiometry of the complex. We then compared the fusion and the unlinked complex using solution nuclear magnetic resonance (NMR) spectroscopy. Most of the cross peaks in the heteronuclear single quantum coherence (HSQC) spectrum of ^15^N-Prdm14 in complex with unlabeled Mtgr1 (where we observe signals only from ^15^N-Prdm14) overlapped with those in the HSQC spectrum of ^15^N-labeled Prdm14-linker-Mtgr1 (where we observe signals from the entire fusion protein including both Prdm14 and Mtgr1) ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). The large number of overlapping peaks in the two spectra strongly suggests that the Prdm14 protein takes on nearly identical average conformation in the unlinked complex and the fusion protein ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). Furthermore, the fusion protein and the unlinked complex had the same affinity to Mb(S4), indicating that the linker did not distort the Prdm14 epitope for the monobody ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). This fusion construct allowed us to overcome the aggregation problem, but it still yielded no crystals in crystallization trials using over 500 conditions.

We then used Mb(S4), the monobody that did not inhibit the Prdm14-Mtgr1 interaction, as a crystallization chaperone. Monobodies, like antibody fragments, often facilitate the crystallization of otherwise recalcitrant systems ([@bib35]; [@bib64]). The addition of Mb(S4) readily led to crystallization of Prdm14-linker-Mtgr1, and we determined its structure to a resolution of 3.06 Å through single wavelength anomalous diffraction (SAD) phasing using selenomethionine-labeled crystals ([Figure 5A](#fig5){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}; [Figure 5---figure supplement 2A](#fig5s2){ref-type="fig"}). The crystallized complex had two Prdm14-linker-Mtgr1/Mb(S4) complexes in the asymmetric unit. As expected, the monobody bound exclusively to Prdm14, burying 604 Å^2^ surface areas, a similar interface size to other monobody/target complexes ([Figure 5---figure supplement 2B, E](#fig5s2){ref-type="fig"}) ([@bib20]; [@bib68]). In the crystal, monobody--monobody interactions facilitated crystal contacts via face-to-face interactions of the β-sheet surfaces (not involved in Prdm14 interaction), illustrating the importance of Mb(S4) as a crystallization chaperone for this complex ([Figure 5---figure supplement 2D](#fig5s2){ref-type="fig"}).10.7554/eLife.10150.020Figure 5.Crystal structure of the Prdm14--Mtgr1 complex.(**A**) The overall structure of the Prdm14-linker--Mtgr1/Mb(S4) complex. Missing residues are shown with dotted lines. The pre-SET region (in orange), SET domain (in yellow) and post-SET region (in green) of Prdm14 are shown. The Mtgr1 helices are marked for clarity (αA--αD). (**B**) Superposition of the Prdm14 crystal structure with the crystal structure of hPRDM12 (PDB ID 3EP0). (**C**) Superposition of the Mtgr1 crystal structure with the NMR structure of the MTG8 NHR1 (eTAFH) domain (PDB ID 2KNH). (**D**) Prdm14--Mtgr1 interface. Prdm14 is shown in white surface representation with the interacting residues in yellow (Top). Mtgr1 is shown in cartoon representation in pink color. In the detailed view, Prdm14 residues are marked in red and Mtgr1 residues are marked in black. Salt bridges and hydrogen bonds between Prdm14 and Mtgr1 are shown in dotted lines. Residues that were mutated based on the structure are underlined. (**E**) Binding of wt, E294K and Y339R Prdm14 (residues 184--373) to immobilized wt Mtgr1 (top) and Mtgr1(K109E) (bottom) in a bead-based assay. (**F**) Mtgr1 is shown in white surface representation with interacting residues in pink (left). Non-identical residues between Mtgr1 and the other ETO proteins are shown in blue (left). The detailed view shows the interaction of Prdm14 residues N-terminal to the SET domain (pre-SET) with Mtgr1 (right). Prdm14 residues are labeled in red and Mtgr1 residues in black. Mtgr1, myeloid translocation gene related 1; NMR, nuclear magnetic resonance.**DOI:** [http://dx.doi.org/10.7554/eLife.10150.020](10.7554/eLife.10150.020)10.7554/eLife.10150.021Figure 5---figure supplement 1.Inclusion of a linker does not affect the Prdm14--Mtgr1 interaction.(**A**) Elution profiles of Prdm14-linker--Mtgr1 (in black) and Prdm14 mixed with Mtgr1 in a 1:2 molar ratio (in red) from a Superdex75 size-exclusion column. (**B**) Overlay of the ^15^N-^1^H HSQC spectrum of ^15^N-Prdm14-linker-Mtgr1 complex (black) with that of ^15^N-labeled Prdm14 in complex with unlabeled Mtgr1 (red). (**C**) Titration curves for binding of Prdm14/Mtgr1 complex and Prdm14-linker-Mtgr1 to Mb(S4). The error bars shown on each data points are the standard deviation from triplicate measurements. The curves show the best fit of the 1:1 binding model. The errors for the *K*~D~ values are the standard deviations from triplicate measurements. Mtgr1, myeloid translocation gene related 1.**DOI:** [http://dx.doi.org/10.7554/eLife.10150.021](10.7554/eLife.10150.021)10.7554/eLife.10150.022Figure 5---figure supplement 2.Structural features of the Prdm14-linker--Mtgr1/Mb (S4) complex.(**A**) Crystals of the Prdm14-linker--Mtgr1/Mb(S4) complex obtained in 16% PEG3350, 8% Tascimate pH 5.3. (**B**) The Prdm14-monobody interface. Prdm14 is shown in white surface representation with the interface residues on Prdm14 shown in yellow and are labeled in black. Mb(S4) is shown in cartoon representation in cyan and are labeled in red. The upper box illustrates prominent features in the interface involving residues in the FG loop of the monobody. Trp81 of Mb(S4) is in the pocket formed by Pro250, Phe270, Val268, Asp262 and Ala265 of Prdm14. Gln75, Tyr77 and Trp81 of Mb(S4) form hydrogen bonds with Prdm14 Arg269, Asp262 and Glu251, respectively. Hydrogen bonds and salt bridges are shown in black dotted lines. The bottom box shows a salt bridge formed between Prdm14 Glu340 and Lys47 in the β-strand C of Mb(S4). (**C**) Unbiased feature-enhanced map showing electron density at the 1 sigma level for residues involved in Prdm14--Mtgr1 interaction. (**D**) Crystal contacts between monobodies and Prdm14 from neighboring molecules. The symmetry related molecules are shown with Prdm14-linker--Mtgr1 in yellow and monobody in cyan. (**E**) Binding of Mb(S4) and its point mutant, Trp81 to Ala, to biotinylated Prdm14 immobilized on streptavidin M280 beads, as measured using the bead-based binding assay. Mutation of Trp81 results in substantial loss of Prdm14 binding, confirming the interface between Prdm14 and Mb(S4) shown in panel B. Mtgr1, myeloid translocation gene related 1.**DOI:** [http://dx.doi.org/10.7554/eLife.10150.022](10.7554/eLife.10150.022)10.7554/eLife.10150.023Figure 5---figure supplement 3.Comparison of the structure of the Prdm14--linker-Mtgr1 complex with that of the Prdm9- histone H3 peptide-S-adenosyl-L-homocysteine (AdoHcy) complex.(**A**) Left, the crystal structure of the Prdm9 complex (PDB ID 4C1Q). Prdm9 is shown in cartoon representation in gray and the histone peptide is shown in sticks in blue. AdoHcy is shown in green sticks. Right, cartoon representation of Prdm14 in gray with Mtgr1 shown in pink ribbon representation. The residues in pre-SET region of Prdm14 that occupy the region equivalent to the AdoHcy binding site in Prdm9 are shown in orange. (**B**) Left, surface representation of Prdm9 in which the surfaces for the atoms within 4.5 Å from the peptide are marked in blue. Right, Mtgr1-interacting residues of Prdm14 are shown in pink. (C). Left, residues in the Prdm9 catalytic site (labeled in black) and the Lys4me2 of the histone peptide (labeled in red), shown in sticks. Tyr357 is directly involved in the catalytic activity of Prdm9. Right, the same region of Prdm14. Phe273 and Tyr339 in Prdm14 are respectively equivalent to Tyr276 and Tyr341 in Prdm9. Lys109 of Mtgr1 present in proximity to the Prdm14-Tyr355 (equivalent to Tyr357 in Prdm9) is shown. Also shown are Pro366 and Glu294 that have atoms within 4.5 Å of Mtgr1-Lys109. Prdm14 residues are labeled in black. K109 of Mtgr1 is labeled in red. Mtgr1, myeloid translocation gene related 1.**DOI:** [http://dx.doi.org/10.7554/eLife.10150.023](10.7554/eLife.10150.023)

The Prdm14 SET domain (residues 240--356) in the crystal structure is flanked by pre-SET and post-SET regions. The crystallization construct includes residues 184--239 that precede the SET domain (pre-SET) and residues 357--373 following the SET domain (post-SET). Unlike many SET domain-containing proteins, Prdm14 does not have cysteine-rich Zn finger domains adjacent to the SET domain, commonly termed pre-SET and post-SET domains. Thus, in the absence of well-defined domains, we refer to these adjacent segments as pre-SET and post-SET regions. The crystal structure of the mouse Prdm14 SET domain is very similar to that of the hPRDM12 SET domain, the closest human homologue of Prdm14 (PDB ID 3EP0; Cα RMSD=0.99; [Figure 5B](#fig5){ref-type="fig"}). The Prdm14 SET domain in our structure has a total of nine β-strands (β1-β9) arranged in three antiparallel β-sheets with a short 3~10~ helix (η1) inserted between β6 and β7. The pre-SET region in our construct has a short helix at the N-terminus followed by a long structurally disordered region a part of which (residues 217--239) has no detectable electron density even at 0.5 σ contour levels (2Fo-Fc). The residues that constitute the post-SET region at the C-terminus to the SET domain are arranged in an antiparallel beta sheet (β10 and β11). Overall, the structural features of the PR/SET domain in Prdm14 show no major differences with other PR/SET domains in Prdm proteins.10.7554/eLife.10150.024Table 1.Data collection, phasing and refinement statistics for Prdm14-linker-Mtgr1/Mb(S4) complex crystals.**DOI:** [http://dx.doi.org/10.7554/eLife.10150.024](10.7554/eLife.10150.024)NativeSeMet SAD**Data collection**BeamlineAPS 19IDAPS 19IDSpace groupP4~3~2~1~2P4~3~2~1~2*Cell dimensionsa, b, c* (Å)106.8,106.8,180.7106.9, 106.9,180.9a, b, g (°)90,90,9090,90,90*Peak*Wavelength0.97918 Å0.97918 ÅResolution (Å)37.7--3.05 (3.16--3.05)50--3.18 (3.23--3.18)*R~pim~*0.024 (0.482)0.022 (0.315)*I* / σ*I*30.0 (1.4)52.4 (2.0)Completeness (%)100 (100)100 (100)Redundancy20.5 (19.5)86.2 (45.2)**Refinement**Resolution (Å)37.7--3.05 (3.16--3.05)No. of unique reflections20631 (2013)*R*~work~ / *R*~free~ 0.189/0.250No. atoms5476Protein5476Ligand/ion0Water0*B*-factors114.3Protein114.3Ligand/ion0Water0R.m.s deviationsBond lengths (Å)0.006Bond angles (°)1.13*Ramachandran statistics*Favorable 95.8Allowed 4.1Outliers 0.1

The Mtgr1 NHR1 domain (also called the TAFH domain) is highly conserved in the ETO family. The Mtgr1 NHR1 domain in the crystal structure contains four well-defined α-helices arranged in a bundle (αA-αD; [Figure 5C](#fig5){ref-type="fig"}). Currently, three NMR structures for the NHR1 domain of human MTG8, another member of the ETO family, are available ([@bib50]; [@bib54]; [@bib67]). Mtgr1 in the crystal structure has almost identical topology as the average solution NMR structure of the NHR1 domain from MTG8 (ETO) in complex with a stabilizing peptide (PDB ID 2KNH; Cα RMSD=1.77 Å; [Figure 5C](#fig5){ref-type="fig"}). Similar structural features and high sequence identity for the NHR1 domain in ETO proteins explain the pull-down of Mtg8 and Mtg16 in the FH-Prdm14 purifications ([Figure 5F](#fig5){ref-type="fig"} (left); [Figure 1A](#fig1){ref-type="fig"}; [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}).

Mtgr1 contacts with the SET domain and pre-SET region of Prdm14 {#s2-7}
---------------------------------------------------------------

The Mtgr1-Prdm14 interaction interface buries 2180 Å^2^, a large interface but still within the observed range for high-affinity protein--protein interaction interfaces with a low nanomolar *K*~D~ value ([@bib8]). We observe that Mtgr1 interacts with both SET domain and pre-SET region of Prdm14 ([Figure 5A](#fig5){ref-type="fig"}), as was predicted from our earlier interaction mapping co-immunoprecipitation experiments ([Figure 1C](#fig1){ref-type="fig"}). The interactions between the Prdm14 SET domain and Mtgr1, mediated primarily by αA and αD, contribute 65% of the total buried surface area. The substantial interaction interface between the pre-SET region and Mtgr1 (35% of the interface) rationalizes the importance of the pre-SET region in the Prdm14-Mtgr1 interaction ([Figure 1C](#fig1){ref-type="fig"}).

Several features in the interface are notable. Arg105 located at the N-terminal end of Mtgr1 αA sits in a pocket formed by Ser290, Met292, Cys319 and Tyr339 of Prdm14 and its guanidinium moiety makes hydrogen bonds with the side chains of all of these residues ([Figure 5D](#fig5){ref-type="fig"}, [Figure 5---figure supplement 2C](#fig5s2){ref-type="fig"}). Mutating Mtgr1 Arg105 to Asp resulted in a loss of detectable binding ([Figure 5E](#fig5){ref-type="fig"}), and replacing Prdm14 Tyr339 of the pocket with Arg substantially reduced binding ([Figure 5E](#fig5){ref-type="fig"}). In addition, Lys109 in Mtgr1 αA interacts with Glu294, Tyr355 and Pro366 of Prdm14 SET domain. Lys109 in Mtgr1 forms a salt bridge with Glu294 from β5 of the Prdm14 SET domain ([Figure 5D](#fig5){ref-type="fig"}). Mutating either of these residues led to a loss of detectable binding ([Figure 5E](#fig5){ref-type="fig"}). Remarkably, charge reversal of this ionic interaction, that is, the combination of Mtgr1 K109E and Prdm14 E294K restored binding, in agreement with the salt bridge formation across the binding interface in solution ([Figure 5E](#fig5){ref-type="fig"} middle). These mutation experiments together supports the authenticity of the binding interface observed in the crystal structure and identified critical electrostatic interactions.

The Mtgr1 interaction with Prdm14 pre-SET region involves residues from Mtgr1 helix αA, αB and αD ([Figure 5A](#fig5){ref-type="fig"}). Several Leu and Val residues from the helix in the pre-SET region contribute to hydrophobic interactions with residues in Mtgr1 helices ([Figure 5F](#fig5){ref-type="fig"}). In addition, Mtgr1 Asn141 forms hydrogen bonds with residues Phe185 and Phe187 from the helix in the pre-SET region. These results further reinforce the observation that Prdm14 utilizes both pre-SET region and SET domain to interact with Mtgr1.

Association of Prdm14 with Mtgr1 is required for mESC maintenance and PGC-LC formation {#s2-8}
--------------------------------------------------------------------------------------

Given strong association between Prdm14 and Mtgr1, as well as phenotypic similarities upon loss of either protein, we next examined whether the lack of Prdm14--Mtgr1 interaction would have a biological effect on mESC gene expression and the efficiency of PGC-LC induction. To this end, we first confirmed that the point mutations designed based on the crystal structure ([Figure 5D and E](#fig5){ref-type="fig"}) also disrupted the interaction between the full-length proteins in cells, and that the combined charge reversal mutations restored the interaction ([Figure 6A](#fig6){ref-type="fig"}). Then, we reconstituted *Stella*:GFP Prdm14^−/−^ mESCs with cDNAs encoding either wt or mutant (E294K or Y339R) FH-Prdm14 and confirmed that all three proteins were expressed at similar levels ([Figure 6B](#fig6){ref-type="fig"}). Next, we used RNA-seq to compare gene expression patterns of these mESCs after transition from 2i+LIF to serum+LIF culture ([Figure 6C](#fig6){ref-type="fig"}). In the Prdm14^−/−^ cells reconstituted with mutant Prdm14, we noted elevated expression of genes associated with differentiation to epiblast and extraembryonic endoderm, and diminished expression of naïve pluripotency genes (with an exception of *Tet2*), similar to attenuated expression patterns (albeit not to the same degree) as we observed upon loss of Prdm14 ([Figure 6C](#fig6){ref-type="fig"}, compare to [Figure 3A](#fig3){ref-type="fig"}). Principal component and clustering based on differential gene expression further support the notion that Prdm14 E294K lines show hypomorphic expression profile, which falls in between the Prdm14^−/−^ ESCs and those reconstituted with wt Prdm14 ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Finally, the efficiency of mPGC-LCs formation from mESC reconstituted with Prdm14 mutants (E294K, Y339R) was significantly diminished compared to cells rescued with the wt Prdm14 to almost the same degree as in *Prdm14^−/−^* cells ([Figure 6D](#fig6){ref-type="fig"}).10.7554/eLife.10150.025Figure 6.Inhibition of Prdm14--Mtgr1 interaction affects stem cell maintenance and PGC-LC induction.(**A**) Single amino-acid substitutions at the interaction surface abrogate Prdm14--Mtgr1 association in cells. Indicated full length V5-Mtgr1 wt or single point mutant proteins were introduced to HEK293 cells and co-immunoprecipitated with full length FH-Prdm14 wt or single mutant protein as indicated in the diagram. Please note rescue of the association when the combination of Mtgr1 K109E and Prdm14 E294K mutants is tested. (**B**) Western blot showing protein expression levels of wt, E294K and Y339R FH-Prdm14 protein in lysates from *Prdm14^−/−^* mESCs cells reconstituted with the respective transgenes. (**C**) RNA-seq from *Prdm14*^−/−^ cells reconstituted with wt Prdm14 protein (x axis) were compared to *Prdm14*^−/−^ cells reconstituted with E294K Prdm14 mutant (y axis) and expression values (RPKM) of all significantly changed transcripts were plotted. The transcripts of specific genes are highlighted in red, green, blue or black as indicated; shaded colors indicate no significant difference. (**D**) Quantification of GFP signal as a measure of mPGC-LC induction from *Prdm14*^−/−^ cells and *Prdm14*^−/−^ cells reconstituted with transgenes encoding wt, E294K, or Y339R Prdm14 protein. (**E**) Schematics of the piggyBac transposon-based reporter system used to create dual reporter lines. mESC line was transfected with either dox-inducible mCherry construct or dox-inducible mCherry-Mb(S14) fusion protein. The lines were selected using blasticidin and three populations were tested further for their competency to form mPGC-LCs. mESC to mEpiLC transition followed by mPGC-LC transition using defined media in cells containing *Stella*:GFP reporter (lower panel). Doxycycline was added after mEpiLC stage. (**F**) Quantification of GFP signal as a measure of mPGC-LC induction from mCherry population of cells and mCherry-Mb(S14) population of cells with and without addition of doxycycline. mEpiLCs, mouse epiblast-like cells; mESCs, mouse embryonic stem cell; mPGC-LCs, mouse primordial germ cell-like cells; GFP, green fluorescent protein; Mtgr1, myeloid translocation gene related 1; RNA-seq, RNA sequencing; RPKM, reads per kilobase of exon per million reads mapped; WCL, whole cell lysates; wt, wild type.**DOI:** [http://dx.doi.org/10.7554/eLife.10150.025](10.7554/eLife.10150.025)10.7554/eLife.10150.026Figure 6---figure supplement 1.Gene expression analyses of Prdm14^−/−^ cells reconstituted with wt or E294K Prdm14.(**A**) PCA of RNA-seq expression comparisons of the top 898 genes with the highest median average deviation in indicated ESC lines. (**B**) Heatmap displaying top 50 variable genes between *Mtgr1^−/−^*(three clones), *Prdm14^−/−^* (2 clones) mESCs or *Prdm14^−/−^* clones reconstituted with wt or mutant (E294K) Prdm14 protein. ESC, embryonic stem cell; PCA, principal component analysis; mESCs, mouse embryonic stem cell; Mtgr1, myeloid translocation gene related 1; RNA-seq, RNA sequencing.**DOI:** [http://dx.doi.org/10.7554/eLife.10150.026](10.7554/eLife.10150.026)10.7554/eLife.10150.027Figure 6---figure supplement 2.Inhibition of Prdm14--Mtgr1 interaction affects germ cell development.(**A**) FACS plots of the gated quantification of GFP signal shown in [Figure 6D](#fig6){ref-type="fig"} as a measure of mPGC-LC induction from wt cells, *Prdm14*^−/−^ cells or *Prdm14^−/−^* clones reconstituted with wt or mutant (E294K, Y339R) Prdm14. (**B**) FACS plots of the gated quantification of GFP signal shown in [Figure 6F](#fig6){ref-type="fig"} as a measure of mPGC-LC induction from three independent populations of mCherry cells or mCherry-Mb(S14) cells with and without addition of doxycycline. FACS, fluorescence-activated cell sorting; GFP, green fluorescent protein; wt, wild type. **DOI:** [http://dx.doi.org/10.7554/eLife.10150.027](10.7554/eLife.10150.027)

Our results thus demonstrate that association of Prdm14 with Mtgr1 is required for mediating its functions in pluripotency and germ cell formation. Given that one of the monobodies we developed, Mb(S14), binds to Prdm14 competitively with Mtgr1, we hypothesized that this reagent can be utilized to inhibit Prdm14 function in living cells or organisms in a highly controlled manner. To provide a proof-of-principle for such strategy, we engineered piggyBac doxycycline-inducible constructs encoding mCherry-Mb(S14) fusion or, as a control, mCherry alone, and introduced them into *Stella*:GFP reporter mESCs ([Figure 6E](#fig6){ref-type="fig"}). Next, we induced mPGC-LC formation from mESCs in the absence or presence of doxycycline (added during the induction of mPGC-LCs from mEpiLCs) to activate monobody expression. We observed consistent reduction in PGC-LC formation efficiency in cells expressing the mCherry-Mb(S14) fusion protein, as compared with the same cell population without addition of doxycycline or to cells expressing mCherry alone ([Figure 6F](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). A more moderate effect of the monobody (compared with the Prdm14 E294K mutation, [Figure 6D](#fig6){ref-type="fig"}) is probably due to the fact that this monobody needs to compete against the high-affinity interaction between Prdm14 and Mtgr1. In addition, we noticed a short half-life of the mCherry-Mb(S14) fusion protein (data not shown), which may contribute to the moderate effect but could also facilitate inhibition with high temporal resolution in the future. Thus, Mb(S14) represents a novel tool that can be utilized to perturb Prdm14 function in living cells during a dynamic biological process such as the PGC induction and can be further modified in the future for addressing particular questions using standard protein-engineering technologies.

Discussion {#s3}
==========

Our study identified the ETO family co-repressor Mtgr1 as a new regulator of mESC identity, which facilitates molecular functions of Prdm14 through direct binding to its pre-SET/SET region. Therefore, although no evidence has been previously found for the catalytic activity of the Prdm14 SET domain, our data demonstrate that this domain is nonetheless essential for Prdm14 function by mediating the interaction with its key partner, Mtgr1. Prdm14 and Mtgr1 co-occupy distal regulatory regions of many target genes linked to differentiation, DNA methylation and chromatin modification, consistent with their tight interaction. Loss of either protein results in upregulation of a subset of these target genes and a gradual loss of mESC self-renewal. However, similar to what has been observed previously for Prdm14, Mtgr1 is not required for maintenance of mESC under 2i+LIF. This can be explained by the fact that the Fgf/Erk pathway, a major signaling cascade driving both epiblast and extraembryonic endoderm differentiation (to which loss of Prdm14/Mtgr1 sensitizes cells), is inhibited under these conditions ([@bib46]).

Concordant upregulation of gene transcripts in *Prdm14^−/−^* or *Mtgr1^−/−^* cells compared with wt mESCs supports function of the Prdm14--Mtgr1 complex in gene silencing and agrees with the reported role of Mtgr1 as an HDAC-recruiting co-repressor ([@bib57]). Notably, we detected HDACs 1--3 in our Prdm14 immunoprecipitates, and HDAC3 and other NCoR1 repressive complex components in our purifications with the Mb(S4) monobody, suggesting that the Prdm14--Mtgr1-dependent repression may indeed be facilitated by histone deacetylation and that Mtgr1 is required for recruiting HDACs to Prdm14-binding loci. Furthermore, although a subset of genomic sites occupied by Mtgr1 occurs at Prdm14 motif-lacking sites, the high similarity of transcriptional changes observed upon loss of either protein suggests that the major impact of Mtgr1 on gene expression and cell identity of mESCs is in the context of its association with Prdm14. Moreover, our data suggest that Prdm14 can not only guide, but through change in its levels, quantitatively tune the degree of interaction of ubiquitously expressed Mtgr1 with chromatin.

Our results from the in vitro PGC-LC formation model strongly suggest that in addition to its role in mESCs, Mtgr1 is also a critical mediator of the Prdm14 function in germline development. Three lines of evidence support this notion: (i) Mtgr1 deletion; (ii) single point mutations in Prdm14 disrupting association with Mtgr1; and (iii) expression of a monobody targeting the Prdm14--Mtgr1 interaction surface, all of which hinder PGC-LC induction in vitro. It is therefore surprising that a *Mtgr1* mouse knockout strain has been reported as viable and fertile ([@bib2]). However, it remains unclear whether this strain represents a true loss-of-function, because in the mouse targeting strategy, the first six exons are preserved (encoding amino acids 1--316, which span the Prdm14 interaction region and NHR2 domain involved in dimerization and association with mSin3/HDAC complex) ([@bib57]). In light of our findings and aforementioned caveats, we suggest that the in vivo function of Mtgr1 in the germline should be revisited. It is also possible, however, that requirement for Mtgr1 in germ cell development in vivo can be fully or partially compensated by the other ETO proteins. Because residues that form the Prdm14 binding interface in Mtgr1 are conserved among the ETO family members, we expect that the other ETO proteins would bind directly to the Prdm14 pre-SET/SET regions and could therefore compensate for the absence of Mtgr1 function.

Our study provides novel insights into how pre-SET and SET regions might mediate high affinity protein--protein interactions. While many structures of the catalytic SET domains have been obtained with their substrates (typically, histone tails), to the best of our knowledge, our study represents the first structural analysis of the SET domain acting as a module for a high affinity protein--protein interaction. Interestingly, a comparison of our structure with that of the Prdm9--AdoHcy--histone peptide complex indicates that the surface of the Prdm14 pre-SET and SET regions engaged in interaction with Mtgr1 overlaps with surfaces other Prdm proteins use for binding to their histone peptide substrate ([Figure 5---figure supplement 3B](#fig5s3){ref-type="fig"}; \[[@bib69]\]). Indeed, Mtgr1 Lys109 is in close proximity to Tyr355 that corresponds to the catalytic Tyr based on the consensus SET domain sequence ([@bib63]). In Prdm9, the catalytic tyrosine Tyr356 along with Tyr276 and Tyr341 form the Lys4me2 binding pocket and are critical for catalytic activity ([@bib69]). In Prdm14, the side chain of Tyr355 flips over (with respect to the conformation of Tyr357 in Prdm9) and interacts with K109 of Mtgr1. The location of K109 is distinct from that of Lys4me2 in Prdm9 ([Figure 5---figure supplement 3C](#fig5s3){ref-type="fig"}). In addition, the high affinity of the Prdm14--Mtgr1 interaction strongly suggests that Mtgr1 would be a poor substrate, given that a substrate needs to be released after catalysis for efficient enzyme reaction. We also note that His211 and Ala212 in the pre-SET region of Prdm14 occupy the S-adenosyl-L-methionine (SAM)-binding site ([Figure 5---figure supplement 3A](#fig5s3){ref-type="fig"}) and thus, at least in the context of the presented structure, preclude the binding of this cofactor necessary for methylation. Taken together, our results suggest that Mtgr1 Lys109 is unlikely to be an actual substrate for Prdm14-mediated methylation. Consistent with this notion, radioactive in vitro methyltransferase assays with recombinant Prdm14 and Mtgr1 proteins, their respective interaction mutants, as well as histone substrates, all failed to yield methyltransferase activity (not shown). However, we cannot exclude the possibility that under presently unknown conditions, such activity can ultimately be found. Regardless, our comparisons suggest that substrate-binding surfaces can, in some SET domain proteins, be co-opted for mediating high affinity protein--protein interactions, which may provide a molecular explanation as to why such surfaces are typically highly conserved even in SET domain proteins with no apparent catalytic activity.

Lastly, aberrant reactivation of the *PRDM14* locus is associated with a variety of human cancers, and mice overexpressing Prdm14 in blood cells develop early-onset T-cell acute lymphoblastic leukemia (T-ALL) ([@bib6]). We speculate that the oncogenic function of Prdm14 may be mediated by the formation of a complex with Mtgr1, which is broadly expressed and thus readily available for association in many different organ systems, or perhaps with other ETO proteins using the same interface. If this proves to be the case, inhibition of the Mtgr1-interaction surface on Prdm14 could be an attractive target for therapy as Prdm14 expression is restricted under non-pathological conditions to the preimplantation embryo and PGCs, reducing the risk of off-target effects on normal somatic tissues. Thus, the monobodies directed to Prdm14 generated in this study will be powerful tools for testing the \'druggability\' of the Prdm14--Mtgr1 interaction. Indeed, we have introduced monobodies into CML cells and demonstrated the potential druggability of a domain interface in Bcr-Abl ([@bib24]). In addition, the crystal structure shows that Mb(S4) binds to a distinct surface of Prdm14. Because monobodies usually bind to functional sites on target proteins, we hypothesize that the Mb(S4) epitope may also be important for Prdm14 function, which will be a subject of future research. We emphasize that the genetically encoded monobodies are portable tools, as they can be readily introduced into different cells via transfection or viral transduction. This attribute should facilitate the investigation of Prdm14 functions in diverse contexts.

Materials and methods {#s4}
=====================

Cell culture, line derivation and embryoid body formation {#s4-1}
---------------------------------------------------------

Stable lines expressing tagged Prdm14 were established from single colonies by transducing LF2 mESCs with FH-Prdm14 pTrip lentivirus for 24 hr, followed by selection with neomycin as described previously ([@bib38]); these lines were used for immunoprecipitations followed by mass spectrometry experiments. *Stella:*GFP cells were a gift from A. Surani and were used for all other experiments and further genetic manipulations, unless indicated otherwise. This line contains a transgene spanning 10 kb upstream of the *Stella* transcriptional start site, exon1, intron1, and part of exon2, followed by *eGFP* fused in-frame and SV40 polyadenylation sequence. *Stella:*GFP line acts as a transcriptional reporter and has been previously shown to faithfully recapitulate endogenous *Stella* expression in mouse and mark PGCs as early as E7.5 ([@bib51]). Stable double reporter lines (*Stella:*GFP and mCherry) were created by transfecting piggyBac Tet-On expression plasmid controlled by rtTA and doxycycline (mCherry alone or mCherry fused to Mb(S14)) with transposase and selected with blasticidin for 7 days. Single clones were picked and expanded further.

For maintenance, all mouse ESC lines were grown in so-called '2i+LIF' medium that is serum-free N2B27-based medium supplemented with MEK inhibitor PD0325901 (0.8 μM) and GSK3β inhibitor CHIR99021 (3.3 μM) in tissue culture (TC) dishes pretreated with 7.5 μg/ml polyl-ornithine (Sigma) and 5 μg/ml laminine (BD) ([@bib28]; [@bib27]). For ChIP-seq, RNA-seq and immunoprecipitation experiments, *Stella*:GFP mESC lines and FH-Prdm14 derivatives were cultured for 5 days in feeder-free conditions in Dulbecco\'s Modified Eagle Medium (DMEM)-high glucose medium (DMEM/high glucose; HyClone) containing 15% (v/v) fetal bovine serum, 1 mM glutamine, penicillin/streptomycin, 0.1mM nonessential amino acids, 0.1 mM 2-mercaptoethanol and supplemented with LIF (serum+LIF conditions).

To form embryoid bodies, Stella:GFP mESCs line of interest was maintained in a 15 cm Petri dish with serum culture medium without LIF, to allow aggregation as a hanging drop with 400 cells per drop (360 drops per mESC line). Cells were cultured for 4 days and half of them were collected for further analysis by RT-qPCR, while the other half was transferred into non-adherent Petri dish and allowed to grow for another 4 days (8 days total) before RT-qPCR analysis.

EpiLC and PGC-LC differentiation {#s4-2}
--------------------------------

To induce mEpiLC differentiation, mESC were washed with phosphate-buffered saline, trypsinized, and strained. A total of about 100,000 cells per one well of 12-well plate were plated on TC dishes pretreated with 5 μg/ml fibronectin (Millipore) in N2B27-based medium supplemented with 1% KSR (Invitrogen) and 12 μg/ml bFGF (Peprotech). The mPGC-LCs were induced similarly to what has been described previously for 6 days ([@bib28]; [@bib27]). Specifically, 1000--2000 mEpiLC cells were aggregated in a hanging drop in a serum-free medium (GMEM, Invitrogen) supplemented with 15% KSR, 0.1 mM NEAA, 1 mM sodium pyruvate, 0.1 mM 2-mercaptoethanol, penicillin/streptomycin, 1 mM glutamine and cytokines 500 ng/ml BMP4 (R&D Systems), 500 ng/ml BMP8a (R&D Systems), 100 ng/ml SCF (R&D systems), 50 ng/ml EGF(R&D systems), LIF. Where indicated doxycycline was added at the point of mPGC-LCs induction from mEpiLCs.

RT-qPCR expression analysis {#s4-3}
---------------------------

Total RNA was isolated with Trizol and afterwards treated with turbo DNase. For reverse transcription of mRNAs, we used 1 μg of DNAse digested RNA, random hexamer primers (5×TransAmp Buffer, Bioline) and reverse transcriptase (Bioline) in 20-μl reaction volume. qPCR analyses were carried out with SensiFAST SYBR No-ROX kit (Bioline) on LightCycler 480 II qPCR machine (Roche).

RNA-seq {#s4-4}
-------

RNAs from at least two independent biological replicates of indicated cell lines were extracted with Trizol (Invitrogen), following the manufacturer's recommendations. Ten micrograms of total RNA were subjected to two rounds purification using Dynaloligo-dT beads (Invitrogen). Purified RNA was fragmented with 10× fragmentation buffer (Ambion) and used for first-strand cDNA synthesis, using random hexamer primers (Invitrogen) and SuperScript II enzyme (Invitrogen). Second strand cDNA was obtained by adding RNaseH (Invitrogen) and DNA Pol I (New England BioLabs). The resulting double-stranded cDNA was used for Illumina library preparation and sequenced with Illumina Genome Analyzer. Following library preparation, samples were pooled and sequenced on an Illumina NextSeq instrument using 76 base-pair single-end reads on a NextSeq high output kit (Illumina) or HiSeq instrument using 51 base-pair single-end reads.

Chromatin immunoprecipitation with sequencing {#s4-5}
---------------------------------------------

ChIP assays were performed from 10^7^ mESC per experiment, according to previously described protocol with slight modification ([@bib55]). Briefly, cells were crosslinked with 1% formaldehyde for 10 min at room temperature and the reaction was quenched by glycine at a final concentration of 0.125 M. Chromatin was sonicated to an average size of 0.5--2 kb, using Bioruptor (Diagenode). A total of 5 μg of antibody was added to the sonicated chromatin and incubated overnight at 4°C. Subsequently, 50 μl of protein G Dynal magnetic beads were added to the ChIP reactions and incubated for \~4 hr at 4°C. Magnetic beads were washed and chromatin eluted, followed by reversal of crosslinks and DNA purification. ChIP DNA was dissolved in water. ChIP-seq and input libraries were prepared according to Illumina protocol and sequenced using Illumina Genome Analyzer. Following library preparation, samples were pooled and sequenced on an Illumina NextSeq instrument using 76 base-pair single-end reads on a NextSeq high output kit (Illumina).

RNA-seq analysis {#s4-6}
----------------

Quality of FASTQ files was assessed using FastQC software. Raw sequencing reads were aligned using Tophat against mm9 genomic index and with refseq gene models as available at illumina.com ftp site. Aligned reads were converted to counts for every gene using HTSeq and gene counts were further analyzed using R and DESeq2 package ([@bib37]). For the scatter plot we identified significantly affected transcripts and plotted RPKMs of transcripts significantly (q\<0.05) affected by Prdm14 or Mtgr1 loss. We compiled from published literature a set of official gene symbols for representative marker genes characteristic for epiblast, extraembryonic endoderm and naïve lineages.

The heatmap was created by looking at top 100 genes with the highest variance across samples (topVarGenes). We looked at the amount by which each gene deviates in a specific sample from the gene's average across all samples; thus, we centered and scaled each gene's values across samples and then plotted a heatmap. To visualize sample-to-sample distances between different lines we used PCA, plotPCA function within DESeq2 package in R on the rlog-transformed counts.

ChIP-seq analysis {#s4-7}
-----------------

Quality of FASTQ files was assessed using FastQC software. ChIPseq peak calls were done with MACS2 callpeak with default settings (<https://pypi.python.org/pypi/MACS2>). Superset of intervals was created by merging summits from all calls using mean shift algorithm with 300 bp bandwidth. The modal peaks were extended ± 300 bp and read coverage was calculated with bedtools. Regions with outlier counts in negative controls were excluded from further analysis.

DNA sequence motif analysis {#s4-8}
---------------------------

Motifs enriched in Mtgr1 ChIP peaks were obtained with SeqPos ([@bib29]), using a set of 1884 coordinates for top Mtgr1 peaks with signal higher in Prdm14 overexpressing cells than in wt cells (Prdm14-dependent) and 1721 Mtgr1 peaks with signal higher in wt cell than in the Prdm14 overexpression background (Prdm14-independent). ChIP regions containing the MTGR1/Prdm14 motif were identified with FIMO with *P* value cutoff set to 0.001. In wt mESCs 64% of Prdm14-dependent sites contain the Prdm14 motif and 16% of Prdm14-independent sites contain the Prdm14 motif (p-value cutoff at 0.0003). This corresponds to odds ratio 9.84 and p\<\<10--16 in Fisher's exact test.

CRISPR/Cas9 targeting {#s4-9}
---------------------

Wt Cas9 plasmid pX330 was obtained from Addgene. The sgRNAs sequences were designed using Zhang Lab website (<http://crispr.mit.edu/>). Guide for Prdm14 was in exon 2 (CGCCGCCGAGGACCAAATTTTGG, score 95) and guide for Mtgr1 was in exon 3 (GACTCTCGTTCTAGCCTTGGTGG, score 78). Note that guides against exons 1, 2, and 3 within Mtgr1 were designed as well as nickase version of Cas9 was used, but only aforementioned guide within exon3 produced mutations that resulted in the loss of protein. *Stella:*GFP mESC line was transfected with the desired sgRNA in pX330 plasmid together with piggyBac mCherry (transient transfection) using Lipofectamine 2000 (Life Technologies) according to the manufacturer's instruction manual. Forty-eight hours post-transfection, we did single-cell sorting into 96-well plates on mCherry-positive cells, assuming that these cells got transfected with both mCherry and pX330 plasmids. The colonies that arose from single cells were screened for the presence of the deletion. The target sequence was amplified by PCR with specific primers from genomic DNA. We then picked a restriction enzyme close to the PAM sequence that upon mutation of the sequence would not be able to cut. For Prdm14, we used *Pfl*MI restriction enzyme, and for Mtgr1, we used *Sty*I restriction enzyme. Clones that could not be digested were further analyzed by doing PCR with specific primers from cDNA and subsequently Sanger sequencing. The results were analyzed with Sequencher 5.1 software and TIDE ([@bib4]). Clones that were confirmed to have a mutation in cDNA were further validated for the presence of protein using Western blotting.

Fluorescence-activated cell sorting {#s4-10}
-----------------------------------

Cells carrying *Stella:*GFP reporter were used to monitor the efficiency of mPGC-LCs formation after 6 days of differentiation. Cells carrying dual reporter constructs (mCherry-S14 Mb and *Stella:*GFP) were PGC-LCs induced for 6 days with doxycycline after which the cells were analyzed. Differentiation was carried out in hanging drops as described. The cells were trypsinized, strained through a 30μm cell strainer and analyzed on an LSR Fortessa Analyzer (BD), data were analyzed further using FlowJo. For statistical analysis, Student's t test was used to compare two normally distributed data sets. The analysis was done in R using unpaired t-test and paired t-test for the same cell population before and after doxycycline treatment. p\<0.05 was considered to be statistically significant.

Immunoprecipitation {#s4-11}
-------------------

Dignam nuclear extracts from mESCs were prepared as previously described ([@bib53]). For immunoprecipitations, monobodies or antibodies that were used are listed in the antibody section below. Typically, 50--100 pmol of monobody and 50 μl of pre-washed M280 dynabeads were used per immunoprecipitation. For immunoprecipitations performed using antibodies, we used 5 μg of antibody and 75 μl of ProteinG-sepharose (Sigma) beads per immunoprecipitation. In double-step IP we first used FLAG M2-beads with peptide elution followed by incubation with HA antibody. If the immunoprecipitation was followed by mass spectrometry peptide identification, then the eluant was run on the one-dimensional SDS-PAGE gel, fixed and excised.

Western blotting {#s4-12}
----------------

Cells were lysed with radioimmunoprecipitation assay buffer (50 mM Tris HCl pH 8, 300 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 1mM ethylenediaminetetraacetic acid \[EDTA\]) containing protease inhibitors (Roche tablet) and 1 mM DTT. The protein concentration was estimated with Bradford reagent (Bio-Rad) and equal or indicated amounts of protein were run on 8% SDS-PAGE gels and transferred to nitrocellulose membranes. Antibodies used in this study are listed in the antibody section.

Protein identification by mass spectrometry {#s4-13}
-------------------------------------------

In gel digestion was performed as previously reported ([@bib62]) with the addition of Protease Max for increased peptide and protein solubility. The extracted peptides were dried using a speed vac and reconstituted in mobile phase A. The ultra performance liquid chromatography (UPLC) was a Waters M-class where mobile phase A was 0.2% formic acid, 5% dimethyl sulfoxide (DMSO), 94.8% water and mobile phase B was 0.2% formic acid, 5% DMSO, 94.8% acetonitrile. The UPLC was run at 300 nl/min from 4% mobile phase B to 35% mobile phase B followed by a wash and re-equilibration step. The mass spectrometer was an Orbitrap Fusion mass spectrometer set to acquire in a data dependent fashion to optimize cycle time and fragment ion acquisition. The RAW data was searched using Byonic against the Uniprot mouse database downloaded on 09/29/2015. The fixed modifications were Cys. propionamide, an the variable Met. oxidation, Asp. deamidation and N-terminal modifications. The data was filtered and presented at a 1% false discovery rate.

Protein expression and purification {#s4-14}
-----------------------------------

An expression vector for human PRDM14 (residues 238--487) with an N-terminal biotin-acceptor tag and C-terminal His~6~ tag based on the p28BIOH-LIC vector (GenBank accession EF442785) was kindly provided by Susanne Gräslund and Cheryl Arrowsmith (Structural Genomics Consortium). The genes for Prdm14 (residues 184--373) and Mtgr1 (residues 98--206) were assembled using synthetic oligonucleotides and cloned in the pHBT vector that adds an N-terminal His~6~ tag followed biotin-acceptor tag and a TEV cleavage site ([@bib61]). The Mtgr1 construct in this vector contained a H200K mutation located outside the NHR1/TAFH domain due to a cloning artifact. For binding assays, all proteins were expressed in BL21 (DE3) cells containing pBirACm plasmid (Avidity) in the presence of 50 μM biotin to produce biotinylated proteins. The Prdm14-Mtgr1 fusion protein was designed to have a GSSGSSGS linker separating Prdm14 (residues 184--373) and Mtgr1 (98--206). The DNA sequences for these genes have been deposited to the GenBank.

All proteins were expressed as His~6~-tagged proteins as described. Proteins were purified using Ni-Sepharose gravity flow columns (GE Healthcare) and the monodispersity of these proteins was assessed by size-exclusion chromatography. For crystallization, the fusion tags were removed using tobacco etch virus (TEV) protease cleavage, and the tags were removed using Ni-Sepharose columns.

Phage display and yeast display-based selection {#s4-15}
-----------------------------------------------

The method of selecting target specific monobodies from phage and yeast display libraries has been previously described ([@bib34], [@bib33]). Two monobody libraries ('loop' and 'side') were used to generate monobodies with diverse binding modes ([@bib34]). Each of these libraries contains approximately 10 billion unique monobody clones in which 16--26 residues are diversified using highly tailored amino acid combinations ([@bib21]; [@bib34]). Four rounds of phage display selection were performed using target concentrations of 100 nM, 100 nM, 75 nM and 50 nM. Streptavidin-coated magnetic beads (Streptavidin MagneSphere Paramagnetic Particles; Promega, Z5481/2) were used for immobilizing the target and captured phages were eluted with 0.1M Gly-HCl, pH 2.1. After gene shuffling among the selected clones within the enriched population ([@bib34]), the monobody-coding genes were transferred into a yeast display vector. We performed library selection by yeast surface display using magnetic beads in the first round followed by two rounds of FACS-based selection. Binding assay for testing the affinity and specificity of individual monobody clones was performed using yeast surface display as described previously ([@bib61]).

Bead-based binding assays {#s4-16}
-------------------------

The general methods for bead-based assays have been described ([@bib48]). In the assay, streptavidin-coated Dynabeads M280 beads (Invitrogen) at 20 μg/ml were incubated with 5 nM biotinylated target protein diluted in BSS/EDTA/DTT buffer (50 mM Tris--HCl, 150 mM NaCl, pH 8, 1 mg/ml bovine serum albumin, 1 mM EDTA, 0.1 mM DTT) for 30 min. The remaining free biotin-binding sites of streptavidin on the M280 beads were blocked with 5 μM free biotin for 30 min. Ten microliters of the target-immobilized beads were transferred to the wells of a 96-well filter plate (MultiScreen HTS HV, 0.45 μm, Millipore), drained using a vacuum manifold (MultiScreen HTS Vacuum Manifold, Millipore), and washed with 100 μl of BSS/EDTA/DTT buffer. Next, a biotinylated protein (biotinylation of the proteins was checked by their ability to bind to streptavidin beads) to be tested at various concentrations was added to individual wells and incubated for 30 min with gentle shaking. Then the wells of the filter plate were washed twice with 150 μl of the buffer, 20 μl of 10 μg/ml SAV-Dylight650 (ThermoFisher) in the buffer was added to the wells, and the plate incubated with shaking for 30 min. The wells were washed again and the beads resuspended in 140 μl buffer and analyzed using a Guava EasyCyte 6/l flow cytometer (Millipore).

Crystallization of the Prdm14-linker--Mtgr1/Mb(S4) complex {#s4-17}
----------------------------------------------------------

Purified Prdm14-linker-Mtgr1 and Mb(S4) were mixed in the molar ratio of 1.0:1.3 and the complex was purified using a Superdex 75 16/600 size exclusion chromatography column (GE Healthcare) in 25 mM Tris pH 8.0, 100 mM NaCl, 0.2 mM TCEP. The protein complex was then concentrated to a final concentration of 15 mg/ml. Initial crystallization screening of \~ 500 conditions was carried out in 96-well plates using the hanging-drop vapor-diffusion method with a crystallization robot (Mosquito, TTP Labtech). Crystals used for data collection were obtained in 17% PEG3350 and 8% Tascimate pH 5.5, and were cryoprotected in 1:1 mix of Paratone and Paraffin oil and flash-cooled in liquid nitrogen prior to data collection. The Prdm14-linker--Mtgr1 protein was labeled with SeMet as described ([@bib16]), purified as a complex with the monobody and crystallized in a similar manner as the native proteins.

Data collection, structure determination and refinement {#s4-18}
-------------------------------------------------------

X-ray diffraction data were collected at Beamline 19ID of the Advanced Photon Source (Argonne National Laboratory, Chicago, IL, USA) ([Table 1](#tbl1){ref-type="table"}). The data were indexed and integrated using HKL3000 ([@bib43]). Molecular replacement using PHASER ([@bib42]) and MOLREP ([@bib66]) with an hPrdm12 structure (PDB ID 3EP0) and the monobody backbone (PDB 3UYO) did not have sufficient scattering power to *generate* a solution with a signal-to-noise ratio that is high *enough* to be identified. Thus, we determined the structure through single-wavelength Se anomalous dispersion experiment. A total of eight Se sites were identified and refined using Autosol ([@bib65]), resulting in an overall figure of merit of 0.45 and Z-score of 43.1. These phases were then used against the SAD data for model building in phenix.autobuild ([@bib1]). Iterative model building and refinement were done using the programs COOT ([@bib17]) and PHENIX ([@bib1]).The structure refined from SAD data was later refined against the higher resolution native data at a 3.05 Å resolution. The final structures were analyzed using Procheck and Molprobity ([@bib11]). Figures were made using Pymol (DeLano, 2002). The structure has 100% residues in the allowed regions of the Ramachandran plot with no outliers. The Molprobity score (2.16) is above average for structures refined at comparable resolutions.

NMR spectroscopy {#s4-19}
----------------

Uniformly ^15^N-labeled Prdm14-linker-Mtgr1 and ^15^N-labeled Prdm14 were prepared by growing bacterial cells in M9 minimal media supplemented with ^15^N-labeled ammonium sulphate (0.8 g l^-1^, Cambridge Isotope Laboratories). The labeled proteins were purified in the same manner as the unlabeled proteins described above. ^15^N-labeled Prdm14 in complex with unlabeled ^14^N-Mtgr1 was purified by gel filtration chromatography. NMR data was collected at 30°C on a 600 MHz Bruker AVANCE III Spectrometer. The samples used for data collection contained 50--200 μM protein in 50 mM Tris-Cl buffer pH 8.0 containing 150 mM NaCl and 0.2 mM TCEP supplemented with 10% D~2~O. All spectra were processed by the NMRPipe software ([@bib14]) and analyzed using SPARKY ([@bib22]).

Antibodies {#s4-20}
----------

Antibodies for Mtgr1 (Western and IP, ab53363, lot GR56108-2,4; ChIP, ab96161), V5tag (Western and IP, ab27671, lot GR186433-4), HA (ChIP, ab9110, lot GR146572-8) were from Abcam, and Suz12 (IP, 04--046) from Millipore. HA antibody (Western and IP, H3663), anti-Flag M2 agarose beads (A2220), M2 Flag antibody (Western, F1804) were from Sigma and dynabeads M280 streptavidin (11205D) were from Life Technologies.
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for submitting your work entitled \"ETO Family Protein Mtgr1 Mediates Prdm14 Functions in Stem Cell Maintenance and Primordial Germ Cell Formation\" for peer review at *eLife*. Your submission has been favorably evaluated by Janet Rossant (Senior editor), a Reviewing editor, and three reviewers.

The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.

Summary:

In this study, the Wysocka and Koide labs have examined how Prdm14, a PR-SET domain transcription factor regulates gene expression. Prdm14 has a critical role in pluripotency in ES cells and in the specification of primordial germ cells (PGCs). They have identified an ETO-family protein Mtgr1 as a co-repressor that binds tightly to the preSET/SET domain as shown by crystal structure of Prdm14-Mtgr1 complex. The authors mapped the domains of both proteins involved in direct interaction, demonstrated (via Chip-seq) that these two proteins tend to recognize the same genomic targets, probably through the DNA binding domain of Prdm14, and indicate that Mtgr1 is required for Prdm14 function in ESCs and PGC formation. Mtgr1 is known for its role in leukemias but had not been previously implied in the regulation of pluripotency and germ line formation. In fact, Mtgr1 null mice appear viable and fertile, suggesting some redundancy in vivo.

The authors also generated a collection of monobodies that either disrupt the interaction between Prdm14 and Mtgr1 or allow the co-immunoprecipitation of the two proteins. Using a monobody that does not inhibit Prdm14-Mtgr1 interaction and a tethered protein construct, the authors obtain crystals of Prdm14-Mtgr1-Mb(S4). The structure was used to analyze the effects of interface mutants.

Overall, the findings are novel and provide information, at least in part, on how Prdm14 functions to repress target genes. Previous studies had indicated Prdm14 interaction with PRC2 and TET1/2, which could not be confirmed in this study. Prdm14 can also activate some genes, but how this occurs remains to be determined in the future.

The authors apply a wide range of approaches, ranging from ESC studies (with knockouts) to structures, monobody generation, and genomics. Indeed, the monobody approach could represent a novel tool to study pluripotency and the regulation of gene expression, and open up mechanisms to target Prdm14 in cancers. With appropriate revisions, this paper is highly suitable for publication in *eLife*.

Essential revisions:

1\) The conclusion from [Figure 2D](#fig2){ref-type="fig"} is that some Mtgr1 bound sites are Prdm14 independent. However, that may not be completely clear based on just over-expression experiments. The authors should acknowledge this (editing the manuscript to be more clear on this point) or add new experiments such as showing Mtgr1 ChIP at \"Prdm14-independent\" sites in a Prdm14 KO ESC line, or upon over-expression of mutant Prdm14 constructs.

Further, it would be informative to know if there are Prdm14 binding sites without Mtgr1. This might indicate that Prdm14 could recruit other interactors to targets, especially to putative targets that might be activated by Prdm14. The authors are encouraged to add new data to clarify these points, or alter the text to be more clear on what is formally shown by the existing data.

2\) The RNA-seq data obtained from ESCs expressing mutant Prdm14 proteins ([Figure 6C](#fig6){ref-type="fig"}) should be shown by PCA analysis and differential gene expression/heatmaps as in [Figure 3B/C](#fig3){ref-type="fig"}, plus some correlation values/GO-terms, to better reveal the similarity between the samples. Also, it seems only one mutant\'s RNA-seq data are shown? Data from at least an n=2 is needed.

3\) Loss of Prdm14 and Mtgr1 in ES cells led to the upregulation of target genes. Careful comparison of the RNA-Seq data might show if there are any differences between them. The authors are encouraged to perform such analyses and clarify which targets are in common and which are distinct.

4\) The study shows that Mtgr1 (like Prdm14) is required for PGC specification. This suggests that Prdm14-Mtgr1 plays a similar role to that in ES cells. While this is a reasonable assumption, it does not discount additional or different targets (repressed and activated) in PGCs. it remains unclear whether Mtgr1 deletion does specifically affect germline differentiation or would lead to a general block in differentiation. Thus, the question remains whether the critical function of Mtgr1 is limited to the germline. The analysis of the self-renewing ESC state in the absence of Mtgr1 is rather limited (only RNA-seq and morphology). Expansion of these analyses to clarify whether Mtgr1 blocks cell differentiation more generally would be welcomed.

5\) Published data on Mtgr1 knockout does not support the proposed role for this gene since the mutant mice are viable and fertile. This remains a major issue to be resolved in light of this study. While other ETO proteins might compensate for Mtgr1 in the germline in vivo, this would also be expected in the in vitro studies on PGCLCs. Some discussion of this conundrum is warranted.

6\) Prdm14 and Mtgr1 should be shown to interact in wt ESCs that are not over-expressing any tagged proteins.

7\) There is quite high percentage (\>10%) of the protein residues located outside of favorable Ramachandran plot, which is unusual. The authors need to check their structure carefully, and/or give an explanation for such large number of residues in non-favorable conformations. For example, what were the values for *R~merge~* or *R~sym~* (in addition to *R~pim~*)?

8\) A covalently linked construct of Prdm14-linker-Mtgr1 was used for crystallization, to overcome the aggregation problem. There could be potential issues with this approach by artificially forcing the two domains together in a certain way. To alleviate these concerns, a specific protease site could be introduced into the linker. The authors could probe whether, after cleavage, the two proteins still associate? Can the same crystal be obtained after adding Mb(S4)? I note that, based on the structure information provided ([Figure 5A](#fig5){ref-type="fig"}), the construct could also be made in the order of Mtgr1-linker-Prdm14. Does this give the same crystal and/or structure? The reviewers find it important to provide data demonstrating that the specific linked construct used did not impact the structure presented.

9\) The work on monobodies is of general interest. Here the work refers to the use of human PRDM14. Is there evidence to show that hPRDM14 can substitute for mouse Prdm14 in ES cells or PGCs? I note in the crystal structure studies that mouse Prdm14 SET domain is similar to human PRDM12 SET domain.

10.7554/eLife.10150.033

Author response

*Essential revisions: 1) The conclusion from [Figure 2D](#fig2){ref-type="fig"} is that some Mtgr1 bound sites are Prdm14 independent. However, that may not be completely clear based on just over-expression experiments. The authors should acknowledge this (editing the manuscript to be more clear on this point) or add new experiments such as showing Mtgr1 ChIP at \"Prdm14-independent\" sites in a Prdm14 KO ESC line, or upon over-expression of mutant Prdm14 constructs.*

In the original manuscript we uncovered two types of Mtgr1 genomic sites: first class contained Prdm14 sequence recognition motif, whereas the second class did not. Based on these observations we referred to the first class as the \'Prdm14-dependent\' and to the second class as \'Prdm14-independent\' sites. We further noted that the first class sites showed robust Prdm14 binding and gain of Mtgr1 ChIP-seq signal in the Prdm14 overexpressing cell line. In contrast, the second class showed low/no Prdm14 binding and diminished occupancy of Mtgr1 upon Prdm14 overexpression. However, we agree with the reviewers that our results did not show directly that Prdm14 is not required for Mtgr1 binding at the second class of sites, and in retrospect, we should have referred to these sites as \'Prdm14 motif-lacking\' sites rather than \'Prdm14-independent\'. This is now rectified in the revised manuscript.

To address the reviewers\' comment further, we have now performed Mtgr1 ChIP-seq from Prdm14^-/-^ ESCs, and generated average signal profiles at Prdm14 motif-containing and Prdm14 motif-lacking sites across all our ChIP-seq datasets (shown in the revised [Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}). The results can be summarized as follows: (i) in wt ESCs, the average Mtgr1 enrichment is similar at Prdm14 motif-containing vs. lacking sites (compare black profiles in left and right panels; note that the scale on the Y axis is the same), (ii) at Prdm14 motif-containing sites, Mtgr1 binding is increased in FH- Prdm14 OE cells and diminished (but not entirely abrogated) in Prdm14^-/-^ cells, left panel, (iii) at Prdm14 motif-lacking sites, Mtgr1 binding is diminished by FH-Prdm14 overexpression, but it is also moderately affected in Prdm14^-/-^ cells (right panel). Altogether, these results are consistent with the Mtgr1 binding to chromatin being sensitive to the Prdm14 dosage (either loss or gain) at the Prdm14-motif containing sites, which are the main focus of our study. However, these results also demonstrate that even in the absence of Prdm14, some Mtgr1 binding remains at the motif-containing sites, suggesting partial redundancies in the recruitment mechanisms. Finally, although quite likely a modest negative effect of Prdm14 deletion on Mtgr1 binding at motive-lacking sites can be attributed to indirect effects (given that these sites show low/no Prdm14 occupancy), we nonetheless concur that it is best to refrain from calling these sites Prdm14-independent.

We have now clarified some of these nuances in the text (subsection "Prdm14 and Mtgr1 co-occupy genomic targets") and also included an additional figure showing the top five sequence motifs recovered at the Prdm14 motif-lacking Prdm14 sites ([Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"}). Of note, the top motif recovered at these sites represents a consensus motif for helix-loop-helix transcription factors, suggesting that a TF from this family may be mediating Mtgr1 recruitment to the Prdm14 motif-lacking sites.

*Further, it would be informative to know if there are Prdm14 binding sites without Mtgr1. This might indicate that Prdm14 could recruit other interactors to targets, especially to putative targets that might be activated by Prdm14. The authors are encouraged to add new data to clarify these points, or alter the text to be more clear on what is formally shown by the existing data.*

We have not been able to detect a class of Prdm14 sites devoid of Mtgr1 binding. This point is illustrated in [Figure 2B](#fig2){ref-type="fig"}, showing Mtgr1 vs. Prdm14 ChIP-seq enrichments at all genomic sites bound by either Mtgr1 or Prdm14 in FH-Prdm14 overexpressing ESCs. If a class of sites bound strongly by Prdm14, but not Mtgr1 existed, than it would show up as a population of sites that have high signal at the X axis and low signal at the Y axis. However, we do not detect such population. As a side note with respect to the previous comment: given that this analysis was out of necessity (as we do not have a ChIP-compatible Prdm14 antibody) done in FH-Prdm14 OE cells, in which Mtgr1 binding at Prdm14 motif-lacking sites is highly diminished, the population of sites that have low value on the X axis and high value on the Y axis (e.g. bound by Mtgr1 and not Prdm14) is also relatively small. Consequently, Mtgr1 and Prdm14 binding patterns in FH-Prdm14 cells are highly correlated (R correlation coefficient \~0.9).

*2) The RNA-seq data obtained from ESCs expressing mutant Prdm14 proteins ([Figure 6C](#fig6){ref-type="fig"}) should be shown by PCA analysis and differential gene expression/heatmaps as in [Figure 3B](#fig3){ref-type="fig"}/C, plus some correlation values/GO-terms, to better reveal the similarity between the samples. Also, it seems only one mutant\'s RNA-seq data are shown? Data from at least an n=2 is needed.*

First, we want to clarify that data from two distinct cell lines reconstituted with Prdm14 E294K mutants were used in our analyses. Following the reviewers\' suggestions, we have now performed the principal component analysis, differential gene expression, and clustering based on distances among our samples, including the two Prdm14^-/-^ cell lines reconstituted with the mutant Prdm14 protein. These data are shown in [Figure 6---figure supplement 1A and B](#fig6s1){ref-type="fig"}. Altogether, these results support the notion that Prdm14 E294K lines show hypomorphic expression profile, which falls in between the Prdm14^-/-^ ESCs and those reconstituted with wt Prdm14. Nonetheless, cells reconstituted with Prdm14 E294K mutant cluster together with Prdm14^-/-^ and Mtgr1^-/-^ cells and away from cells rescued with wt Prdm14 ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). When considering PCA plot in [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}, please note the following: (i) cells reconstituted with wt Prdm14 have a gain-of-function phenotype, which results in tighter repression of differentiation genes and makes their gene expression profile look more like that of ESCs grown under 2i+LIF, even when they are maintained under serum, (ii) wt and mutant reconstituted cell lines show comparable Prdm14 overexpression levels.

*3) Loss of Prdm14 and Mtgr1 in ES cells led to the upregulation of target genes. Careful comparison of the RNA-Seq data might show if there are any differences between them. The authors are encouraged to perform such analyses and clarify which targets are in common and which are distinct.*

We have performed careful analysis of all genes that are upregulated at least twofold upon knockout of either Prdm14 or Mtgr1 (datasets from multiple clonal knockout lines have been considered for each), and we color coded them based on whether they are statistically significantly affected in one or both set of knockout samples ([Figure 3---figure supplement 4B](#fig3s4){ref-type="fig"} in the revised manuscript). The majority of genes upregulated in either knockout is upregulated in both (purple dots). However, there is also a subset of genes that show significant upregulation only in Mtgr1 null cells (blue dots) or only in Prdm14 null cells (red dots). To our knowledge, these differential genes do not appear to be associated with a coherent biological function or phenotype. Nonetheless, to facilitate further follow up work we have incorporated gene names for these uniquely upregulated transcripts into the figure.

*4) The study shows that Mtgr1 (like Prdm14) is required for PGC specification. This suggests that Prdm14-Mtgr1 plays a similar role to that in ES cells. While this is a reasonable assumption, it does not discount additional or different targets (repressed and activated) in PGCs. it remains unclear whether Mtgr1 deletion does specifically affect germline differentiation or would lead to a general block in differentiation. Thus, the question remains whether the critical function of Mtgr1 is limited to the germline. The analysis of the self-renewing ESC state in the absence of Mtgr1 is rather limited (only RNA-seq and morphology). Expansion of these analyses to clarify whether Mtgr1 blocks cell differentiation more generally would be welcomed.*

We thank the reviewers for raising this important point. To test whether loss of Mtgr1 results in general block of cell differentiation, we induced embryoid body (EB) formation from wild type and Mtgr1^-/-^ mESCs and analyzed expression of differentiation markers by RT- qPCR at day 4 and day 8 after induction. We detected comparable expression of markers representing all three germ layers in wild type and Mtgr1^-/-^ EBs (these results are shown in [Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}). Although we cannot exclude a possibility that Mtgr1^-/-^ cells show differentiation defects in specific somatic lineages, our data are inconsistent with a general block in differentiation.

*5) Published data on Mtgr1 knockout does not support the proposed role for this gene since the mutant mice are viable and fertile. This remains a major issue to be resolved in light of this study. While other ETO proteins might compensate for Mtgr1 in the germline in vivo, this would also be expected in the in vitro studies on PGCLCs. Some discussion of this conundrum is warranted.*

We agree that this is a conundrum, as based on our results one would expect a germline phenotype in Mtgr1 knockout mouse, unless a stronger selection for the compensation by other ETO proteins occurs in vivo than in the vitro derived cells. Nonetheless, there are also caveats associated with the described targeting strategy in published Mtgr1 knockout mice, namely the first six exons encoding amino acids 1-316 (spanning the Prdm14 interaction region as well as NHR2 domain involved in dimerization and association with mSin3/HDAC complex), are still preserved (Amann et al., 2005; Rossetti et al., 2004). Thus, this mutant strain is likely hypomorphic. Furthermore, through a symposium presentation earlier this year we became aware of another Mtgr1 knockout study using a different targeting strategy, in which homozygous null mice showed very strong defects in both male and female germline. However, given that this work is as of yet unpublished and we are not familiar with all experimental details, unfortunately we cannot comment on these distinct results in our manuscript. We therefore hope that the reviewers can understand that we keep the discussion of the apparent discrepancy fairly succinct (from main text Discussion section):

"It is therefore surprising that Mtgr1 mouse knockout strain has been reported as viable and fertile (Amann et al., 2005). However, it remains unclear whether this strain represents a true loss-of-function, because in the mouse targeting strategy the first six exons are preserved (encoding amino acids 1-316 which span the Prdm14 interaction region and NHR2 domain involved in dimerization and association with mSin3/HDAC complex) (Rossetti et al., 2004). In light of our findings and aforementioned caveats, we suggest that the in vivo function of Mtgr1 in the germline should be revisited. It is also possible, however, that requirement for Mtgr1 in germ cell development in vivo can be fully or partially compensated by the other ETO proteins."

*6) Prdm14 and Mtgr1 should be shown to interact in wt ESCs that are not over-expressing any tagged proteins.*

While IP experiments with endogenous proteins were initially hampered by the lack of suitable antibodies recognizing mouse Prdm14, we were now able to perform these analyses by taking advantage of our monobodies, which we used to precipitate endogenous Prdm14 from wild type ESCs. Immunoblot analysis with α-Mtgr1 antibody showed that Mb(S4) monobody, which does not disrupt Prdm14-Mtgr1 interaction, but not Mb(S14) monobody, which binds competitively, recovers endogenous Mtgr1 (and is able to deplete most of it from the extract). These data are now part of [Figure 4---figure supplement 2A and B](#fig4s2){ref-type="fig"}. In addition, we now performed Prdm14 Mb(S4)-precipitation/mass spec analysis from wt ESCs, which readily detected Mtgr1-originating peptides ([Figure 4---figure supplement 2C](#fig4s2){ref-type="fig"}).

*7) There is quite high percentage (\>10%) of the protein residues located outside of favorable Ramachandran plot, which is unusual. The authors need to check their structure carefully, and/or give an explanation for such large number of residues in non-favorable conformations. For example, what were the values for* R~merge~ *or* R~sym~ *(in addition to* R~pim~*)?*

We thank the reviewer(s) for suggesting the possibility of improving the structure. We have now reexamined the structure and indeed we have been able to improve its geometries. The new structure has 95.8% favorable, 4.1% allowed and 0.1% outliers, which we consider as acceptable statistics. In addition, the newly refined structure has improved *R/R~free~* values of 0.189/0.250. The improved structure no longer has statistically unusual features.

*8) A covalently linked construct of Prdm14-linker-Mtgr1 was used for crystallization, to overcome the aggregation problem. There could be potential issues with this approach by artificially forcing the two domains together in a certain way. To alleviate these concerns, a specific protease site could be introduced into the linker. The authors could probe whether, after cleavage, the two proteins still associate? Can the same crystal be obtained after adding Mb(S4)? I note that, based on the structure information provided ([Figure 5A](#fig5){ref-type="fig"}), the construct could also be made in the order of Mtgr1-linker-Prdm14. Does this give the same crystal and/or structure? The reviewers find it important to provide data demonstrating that the specific linked construct used did not impact the structure presented.*

We appreciate the importance of explicitly supporting the authenticity of the structure determined with the use of a flexible linker, although connecting an interacting pair of proteins with a flexible linker is a common approach to stabilize the complex while retaining its biological function. This linker strategy is well accepted among crystallographers (Ernst et al., 2014; Kobe et al., 2015; Reddy Chichili et al., 2013; Zhou et al., 2015). The linker we used in this work is similar to those used for the single-chain Fv form of antibodies in which the light and heavy chain domains are linked. There are thousands of single-chain Fv molecules that are fully functional and most likely retain the native conformation. Whereas the approach suggested by the reviewers is intriguing, the difficulties in handling the Mtgr1 protein at high concentrations and our complete failure in crystallizing unlinked constructs even with the monobody strongly suggest that it would be a long-term project in itself. Therefore, we have taken different approaches using NMR spectroscopy and affinity measurements and produced additional data that strongly support the authenticity of the structure.

First, we compared the ~1~H-~15~N HSQC spectrum of ~15~N-Prdm14 in complex with unlabeled Mtgr1 against that of ~15~N-labeled Prdm14-linker-Mtgr1 fusion. Because the amide NMR chemical shifts are exquisitely sensitive to the local conformation and each amino acid residue (except for proline) gives rise to an HSQC cross peak, a ~1~H-~15~N HSQC spectrum gives a comprehensive fingerprint of an ~15~N-labeled protein. Most of the cross peaks in the HSQC spectrum of ~15~N-Prdm14 in complex with unlabeled Mtgr1 (shown in red in [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}; where we observe signals only from ~15~N-Prdm14) overlapped with those in the HSQC spectrum of ~15~N-labeled Prdm14-linker-Mtgr1 (shown in black; where we observe signals from both Prdm14 and Mtgr1). The high levels of coincided peaks in the two spectra strongly suggest that the Prdm14 protein takes on nearly identical conformation in the unlinked complex and in the fusion protein ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). Please also note that the spectrum for ~15~N-Prdm14 in complex with unlabeled Mtgr1 was of poorer quality because we needed to keep its concentration low to prevent aggregation.

Second, we determined the affinity of Mb(S4) to the Prdm14-linker-Mtgr1 fusion and to the Prdm14/Mtgr1 complex. The dissociation constants of Mb(S4) to these two samples were identical ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}), indicating that the epitope for Mb(S4) on Prdm14 is not distorted by the introduction of the linkage between Prdm14 and Mtgr1.

In addition to the new data described above, we would like to note the following points already in the original manuscript that support the crystal structure:

i\) The linked molecule maintained the 1:1 heterodimer architecture of the separate Prdm14-Mtgr1 complex in solution and in the crystal. Therefore, the linkage did not introduce gross changes to the complex, such as oligomerization due to 3D domain swapping (reviewed in (Liu and Eisenberg, 2002)). The size-exclusion chromatography data are now included as [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}.

ii\) The linker used in our work is sufficiently long to allow the two domains to move freely. The distance between the beginning and end of the linker in the observed structure is \~18 Å, whereas the polypeptide connecting these points include eight residues that can span more than 24 Å even using a conserved (i.e. short) distance estimate of 3 Å per residue. Accordingly, the linker makes a U-turn in the structure and it cannot impose steric strain (\"pull\") between the two domains. Indeed, several residues within the linker are undetected, suggesting that they are flexible and not under tension. In retrospect, the dotted straight lines in original [Figure 5A](#fig5){ref-type="fig"} may have given a false sense of tension or distortion in the structure. We have replaced the line with a curve that more accurately reflects the actual length of the linker.

iii\) The reviewer suggested, \"*To alleviate these concerns, a specific protease site could be introduced into the linker. The authors could probe whether, after cleavage, the two proteins still associate?\"* We have shown that free Prdm14 and Mtgr1 associate with high affinity ([Figure 1E and 1F](#fig1){ref-type="fig"}), which in our opinion has already answered this question.

iv\) The mutation data ([Figure 6](#fig6){ref-type="fig"}) validate the authenticity of the observed interface including a specific ionic interaction in the full-length Prdm14 and Mtgr1 proteins, and show that structure-based mutations affect key biological functions of Prdm14.

Altogether, we hope that this extensive series of results convinces reviewers that the linker strategy used here introduced little if any perturbation to the conformation of the Prdm14/Mtgr1 complex. In order to clarify this important point, we have added a paragraph that summarizes the discussion above (subsection "Generation of renewable monobody reagents to study and inhibit Prdm14-Mtgr1 complex").

*9) The work on monobodies is of general interest. Here the work refers to the use of human PRDM14. Is there evidence to show that hPRDM14 can substitute for mouse Prdm14 in ES cells or PGCs? I note in the crystal structure studies that mouse Prdm14 SET domain is similar to human PRDM12 SET domain.*

First, we would like to point out that our monobodies recognize mouse and human Prdm14 with similar affinities ([Figure 4B](#fig4){ref-type="fig"}). Regarding the second part of the comment: a question whether hPRDM14 can complement defects observed upon loss of the mouse protein has, to our knowledge, never been addressed. Therefore, to answer reviewer\'s point, we cloned hPRDM14 cDNA, and introduced it to mouse Prdm14~-/-~ ESCs using a piggyBac system. We subsequently compared tagged Prdm14 levels (by immunoblotting), cell morphology and expression of select Prdm14-bound genes (by RT- qPCR) in Prdm14~-/-~ ESCs reconstituted with either mouse or human Prdm14 (shown in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). These analyses revealed that at least with respect to ESC functions, the hPRDM14 could substitute for the mouse protein (see subsection "Generation of renewable monobody reagents to study and inhibit Prdm14-Mtgr1 complex").

[^1]: These authors contributed equally to this work.
